

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The validity of the Rx-Risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-021122
Article Type:	Research
Date Submitted by the Author:	12-Dec-2017
Complete List of Authors:	Pratt, Nicole; University of South Australia, Sansom Institute for Health Research Kerr, Mhairi ; University of South Australia, Sansom Institute for Health Research Barratt, John; University of South Australia, Sansom Institute for Health Research Kemp-Casey, Anna; University of South Australia, Sansom Institute for Health Research Kalisch Ellett, Lisa; University of South Australia, Sansom Institute for Health Research Ramsay, Emmae; University of South Australia, Sansom Institute for Health Research Roughead, Elizabeth; University of South Australia, Sansom Institute for Health Research
Keywords:	chronic disease burden, comorbidity, mortality prediction, model validation, claims data, weighting

SCHOLARONE™
Manuscripts

Title: The validity of the Rx-Risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system

Authors: Pratt N^a, Kerr M^a, Barratt J^a, Kemp-Casey A^a, Kalisch Ellett L^a, Ramsay E^a, Roughead EE^a.

- a. Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia.

Corresponding Author: Nicole Pratt,

Postal address: Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471, Adelaide, SA 5001, AUSTRALIA.

Email: nicole.pratt@unisa.edu.au

Phone: +618 8302 2818

Nicole Pratt, University of South Australia, Adelaide, Australia

Mhairi Kerr, University of South Australia, Adelaide, Australia

John Barratt, University of South Australia, Adelaide, Australia

Anna Kemp-Casey, University of South Australia, Adelaide, Australia

Lisa Kalisch Ellett, University of South Australia, Adelaide, Australia

Emmae Ramsay, University of South Australia, Adelaide, Australia

Elizabeth Ellen Roughead, University of South Australia, Adelaide, Australia

Key words: chronic disease burden, claims data, comorbidity, weighting, mortality prediction, model validation.

Word Count: 2819

Abstract (300 words allowed)

Objectives: To validate the Rx-Risk comorbidity index for medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system codes.

Design: The 46 comorbidities in the Rx-Risk index were mapped to dispensing's indicative of each condition using ATC codes. Prescription dispensing claims in 2014 were used to calculate the Rx-Risk. A baseline logistic regression model was fitted using age and gender as covariates. Rx-risk was added to the base model as an (i) unweighted score, (ii) weighted score, and as (iii) individual comorbidity categories indicating the presence or absence of each condition. The Akaike information criterion (AIC) and c-statistic were used to compare the models.

Setting: Models were developed in the Australian Government Department of Veterans' Affairs health claims data and external validation was undertaken in a 10% sample of the Australian Pharmaceutical Benefits Scheme Data.

Participants: Subjects aged 65 years or older

Outcome measures: Death within one year (eg 2015)

Results: Compared to the base model (c-statistic 0.738, 95% Confidence Interval (CI) 0.734-0.742), including Rx-Risk improved prediction of mortality; unweighted score 0.751, 95%CI 0.747-0.754, weighted score 0.786, 95%CI 0.782-0.789 and individual comorbidities 0.791, 95%CI 0.788-0.795. External validation confirmed the utility of the weighted index (c-statistic=0.833).

Conclusions: Rx-Risk strongly predicted one-year mortality, however, modelling Rx-Risk as individual covariates may be most useful in practice.

1
2
3 **Strength and Limitations of this study (5 bullet points that relate to methods. No results)**
4

5 Strengths

- 6
7
 - 8 • This study provides an up to date list of medicines identified by ATC codes mapped
9 to individual Rx-Risk categories
 - 10
11 • Rx-Risk mapped to ATC codes can be easily adapted for use in other health systems
12 making this index a useful resource for researchers worldwide

13
14
15

16 Limitations

- 17
18
 - 19 • The Rx-Risk index has been updated and mapped to ATC codes based on medicine
20 availability in Australia; hence modifications may be required for use in other health
21 systems
 - 22
23 • This study was limited to patients over 65 years of age so Rx-Risk category weights
24 derived in this study may not be applicable to younger populations.

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The prevalence of multi-morbidity in the population is increasing [1, 2] and patients with multiple conditions are at greater risk of adverse outcomes [3]. In observational studies in which the aim is to determine the association between medicine use and adverse events, adjustment for multi-morbidity is required to avoid biased results. Reliable methods for identifying and controlling for multiple comorbidities are required in order to make valid comparisons between treatments. The Rx-Risk is a measure for determining an individual's current comorbidities based on their prescription medicine dispensing [4, 5]. It was initially developed for predicting costs of health care [6] and was subsequently adapted to predict mortality in outpatient populations [7, 8]. Rx-Risk has been found to be a better predictor of one- and three-year mortality (one-year mortality: weighted Rx-Risk c-statistic=0.728, 95% CI=0.723-0.733, three-year mortality: 0.731, 95%CI=0.728-0.734) compared to simple prescription counts in the same time periods (one-year mortality: 0.715, 95%CI=0.710-0.720, three-year mortality: 0.718, 95%CI=0.715- 0.721) [9].

The first pharmacy based measure of comorbidity, developed in 1992, was The Chronic Disease Score (CDS) [4], consisting of 17 comorbidity categories. The CDS was subsequently updated and renamed in 2003 as the Rx-Risk-V index, consisting of 45 categories of comorbidity [10]. The Rx-Risk-V index was then adapted to only include comorbidities for which a medicine could be prescribed and therefore could be applied to prescription claims data resulting in an index based on 42 categories of comorbidity [11]. Due to continual advances in pharmaceutical disease management and as new medicines are used to treat particular diseases, e.g. treatment for hepatitis B and C, the Rx-Risk requires periodical updating and re-validation. A list of Rx-Risk comorbidities and their corresponding medicines

1
2
3 mapped to a standardised international coding system would facilitate use of the index
4
5 across health systems. Other comorbidity scores such as the Elixhauser and Charlson Index
6
7 [12, 13] require diagnostic information in their construction. The advantage of the RxRisk is
8
9 that it requires prescription data only and provides researchers with the ability to measure
10
11 comorbidity even in a predominately outpatient setting.
12
13

14
15
16 To facilitate the use of the RxRisk in practice, this paper provides a list of the individual
17
18 RxRisk categories mapped, using clinical expertise, to the World Health Organisation's
19
20 Anatomical Therapeutic Chemical (ATC) classification system [14]. The aim of this study was
21
22 to determine the validity of the Rx-Risk index, in predicting one-year mortality in an
23
24 outpatient population.
25
26
27
28
29

30 **Method**

31 32 33 34 **Rx-Risk index mapping**

35
36 The Rx-Risk index consists of 46 comorbidity categories. For each Rx-Risk category,
37
38 medicines indicative of that condition were mapped (see Table 1). This mapping was
39
40 performed at the ATC classification level and performed by consensus between two
41
42 pharmacists. If an individual had ≥ 1 dispensing for a medicine in a given category then they
43
44 were considered to have been treated (using medicines) for that comorbidity.
45
46
47

48 **Data sources**

49
50 The primary data source was the Australian Government Department of Veterans' Affairs
51
52 (DVA's) administrative claims database. This database contains details of all prescription
53
54 medicines, medical and allied health services, and hospitalisations subsidised by DVA. The
55
56
57
58
59

1
2
3 current treatment population consists of 223,181 members of the Australian veteran
4 community, which includes veterans, war widows and widowers. The median age of the
5 DVA treatment population is 75 years and 62% are men. DVA also maintains a client file
6 containing gender, date of birth and date of death information.
7
8
9

10
11 External validation of the Rx-Risk index was conducted using the Pharmaceutical Benefits
12 Scheme (PBS) 10% sample of the Australian population. This dataset contains information
13 on the dispensing of prescription medicines, and includes basic demographic information
14 regarding gender, year of birth and year of death. It is maintained by the Australian
15 Government Department of Human Services. The current treatment population consists of
16 1,346,340 members of the Australian community. The median age of the PBS treatment
17 population is 43 years and 48% are men.
18
19
20
21
22
23
24
25
26
27

28 Medications in both the DVA and PBS datasets are coded using the World Health
29 Organisation anatomical therapeutic chemical (ATC) classification system [14] and PBS item
30 codes [15].
31
32
33
34

35 **Study population**

36
37 The DVA study population included individuals with at least one health care encounter in
38 the six month period from 1 July 2013 to 31 December 2013. A health care encounter
39 included any of the following: a medication dispensing, a doctor's visit, or hospitalisation.
40
41
42
43
44 Analysis was restricted to veterans who were DVA Gold Card holders prior to 1 July 2013
45 (ensuring they were eligible for all DVA subsidised services, thus the data set captured all
46 their health claims), and were between the ages of 65 and 100 years at 1 January 2015
47 (N=135,406). Inclusion criteria for the PBS cohort were people with a health care encounter
48 (defined as at least one medicine dispensing) in the six month period from 1 July 2013 to 31
49 December 2013, who were aged between 65 and 100 years at 1 January 2015 (N=303,135).
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The primary outcome for this study was death recorded in 2015. Rx-Risk scores were
4
5 calculated separately in each dataset over a one-year baseline period (1 January 2014 – 31
6
7 December 2014).
8

9 **Calculating Rx-Risk scores and prescription counts**

10
11 The full Rx-Risk index has 46 comorbidity categories; however, tuberculosis, and hepatitis B
12
13 and C were removed from the Rx-Risk index for this study as the number of individuals with
14
15 these conditions in the DVA cohort was less than 10 so weights could not be generated. This
16
17 resulted in 43 categories in the validation study. The following forms of the Rx-Risk score
18
19 were generated. The unweighted Rx-Risk score was calculated as the count of the number
20
21 of different comorbidity categories for which an individual was treated with a possible score
22
23 ranging from 0 to 43. The weighted Rx-Risk score was calculated by adding the 43 indicator
24
25 variables to a logistic regression model with mortality as the outcome and age and gender
26
27 as predictors. From this model each comorbidity was assigned a weight according to the
28
29 statistical significance and magnitude of the resulting odds ratio (Table 2)[7]. The weighted
30
31 Rx-Risk score for an individual was then the sum of the weighted indicator variables.
32
33
34
35
36

37 *[Insert Table 2 here]*
38
39
40
41

42 Three crude prescription counts were also calculated: (i) total number of prescriptions
43
44 dispensed in the baseline period (1 January 2014 – 31 December 2014), (ii) total number of
45
46 unique medicines dispensed in the baseline period based on ATC codes, and (iii) total
47
48 number of unique medicines dispensed during the baseline period based on PBS item
49
50 codes[15]. The distinction between ATC and PBS codes was made because different
51
52 strengths or formulations of the same medicine have the same ATC code but different PBS
53
54 codes; e.g. if a patient is dispensed two different strengths of the same medicine, this will be
55
56
57
58
59

1
2
3 counted once in the total number of ATC medicines dispensed but twice in the total number
4
5 of PBS medicines dispensed.
6
7
8
9

10 **Statistical analysis**

11
12 Primary analysis was performed in the DVA database. A baseline logistic regression model
13
14 was calculated for mortality using age and gender as predictors. The comorbidity scores,
15
16 individual comorbidities, and crude prescription counts were added to the baseline model
17
18 separately. Age, comorbidity scores and crude prescription measures were included in the
19
20 models as continuous variables assuming linear associations. The overall goodness-of-fit of
21
22 each model was compared to the baseline model using the Akaike Information criterion
23
24 (AIC)[16]. The model with the lowest AIC value is considered the best fit. The difference
25
26 between the AIC values of two models must be greater than 10 for one model to be
27
28 considered superior to the other. Model discrimination was compared based on the c-
29
30 statistic and the relative Integrated Discrimination Improvement (IDI) [17]. The value of the
31
32 c-statistic can range from 0 to 1, with 1 indicating perfect prediction and 0.5 indicating
33
34 chance predictions. A c-statistic between 0.8–0.9 is generally considered as excellent, and
35
36 between 0.7–0.8 acceptable[18]. Using 1000 bootstrap samples 95% confidence intervals
37
38 were calculated for the c-statistics[9].
39
40
41
42
43
44
45
46
47

48 **Internal validation of weighted scores**

49
50 We used 10-fold cross-validation to internally validate the binary logistic regression model
51
52 used to calculate the Rx-Risk category weights. This subsets the DVA cohort, using random
53
54 sampling without replacement, into 10 equal folds. Each fold is a 10% subset of the DVA
55
56 cohort. The training set consisted of 9 folds and was used to calculate Rx-Risk category
57
58
59
60

1
2
3 weights. The calculated weights were then applied to the testing set (i.e. fold left out of
4 training set). A binary logistic regression model of one- year mortality including age, gender
5 and weighted Rx-Risk was built separately for the training set and testing set and the c-
6 statistics recorded. This process was repeated ten times until each fold was used as the
7 testing set once. This resulted in 20 c-statistics being calculated, 10 each on the training and
8 testing set. The average c-statistic was recorded for each set.
9
10
11
12
13
14
15

16
17
18
19 Two sensitivity analyses were carried out. In the first sensitivity analysis we used the lower
20 confidence limit of the odds ratio to determine the Rx-Risk category weights rather than the
21 estimated odds ratio itself. We did this as some comorbidities are uncommon in this
22 population resulting in large confidence intervals. In the second sensitivity analysis we
23 calculated the Rx-Risk category weights (based on the odds ratio) generated from 5000
24 bootstrap samples. For each Rx-Risk category the weight was calculated as the median of
25 the 5000 weights for that category generated in each bootstrap sample. We did this
26 sensitivity analysis to test the stability of the weights.
27
28
29
30
31
32
33
34
35
36
37
38

39 **External Validation**

40
41 Using the same methods described above we also derived Rx-Risk category weights in the
42 PBS data and compared them to the base model in this dataset. Additionally, we compared
43 unweighted scores, individual Rx-Risk categories, and crude prescription counts to the base
44 model. To determine the external validity of the weights, the calculated Rx-Risk category
45 weights derived from the DVA dataset were applied to the PBS cohort, and vice versa. The
46 Akaike information criterion model fit and c-statistics were calculated to determine the
47 validity of the models.
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Table 1 presents the ATC mapped Rx-Risk categories, derived empirical weights, and number of treated individuals within the DVA and PBS populations. The most frequent comorbidities identified by the Rx-Risk index in the DVA cohort were hypertension (53%), gastro-oesophageal reflux disease (GORD) (51%), hyperlipidaemia (50%), and conditions treated with antiplatelets (39%). In the DVA cohort of 135,406 people, with an average age of 83 years (standard deviation (SD) 9.5) and 47% were men. The median unweighted Rx-Risk score was 5 (interquartile range (IQR) 3-7) and the median weighted Rx-Risk score was 3 (0-6).

The baseline model, comprising only age and gender, predicted one-year mortality moderately well in the DVA cohort (c-statistic=0.738, 95% Confidence Interval (CI) 0.734-0.742). The addition of Rx-Risk to the model increased the performance of the model: unweighted Rx-Risk c-statistic=0.751, (95% CI 0.747-0.754), IDI=14.0%, p-value<.0001; weighted Rx-Risk c-statistic=0.786, (95% CI=0.782-0.789), IDI=65.6%, p-value<.0001; 43 individual comorbidities c-statistic=0.791, (95% CI=0.788-0.795), IDI=73.9%, p-value<.0001. The model including the 43 comorbidity indicator variables had the lowest AIC (75692), highest c-statistic (0.791), and the highest discrimination improvement (73.9%). The models including the weighted Rx-Risk score or 43 comorbidity measures were better predictors of one-year mortality than any of the crude prescription measures (Table 3). Results of the internal 10-fold cross validation were consistent with the main analysis with an average c-statistic of 0.785 achieved over the 10 testing datasets compared to a c-statistic of 0.786 in the primary analysis.

[Insert Table 3 here]

1
2
3
4
5 In the sensitivity analysis using the lower 95% confidence interval limit in the weighting
6 algorithm we found a very similar performance with a c-statistic of 0.787 compared to the
7 weighting algorithm using the estimated odds ratio (c-statistic 0.786). In the second
8 sensitivity analysis in which the weights were calculated from 5000 bootstrap samples we
9 found a similar c-statistic (0.786) compared to the primary analysis.
10
11
12
13
14
15
16
17
18

19 The PBS cohort consisted of 303,135 people, with an average age of 75 years (standard
20 deviation (SD) 7.4) and 45% were men. Similar to the DVA cohort, the most frequent
21 comorbidities identified by the Rx-Risk index in the PBS cohort were hypertension (54%),
22 hyperlipidaemia (52%) and gastro-oesophageal reflux disease (GORD) (41%). The median
23 unweighted Rx-risk score was 4 (2-6) and the median weighted Rx-Risk score was 3 (0-7).
24 When the DVA derived Rx-risk category weights were applied to the PBS population we
25 found a c-statistic of 0.833 (Table 3).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Compared to the base model including just age and gender in the PBS population (c-statistic
50 0.761), the Rx-Risk index treated as individual covariates was most predictive of one-year
51 mortality in this cohort (c-statistic= 0.845, (95% CI 0.842-0.849), IDI=114.8%, p-value<.0001)
52 and performed better than all other forms of the Rx-Risk score.
53
54
55
56
57
58
59
60

Discussion

This paper presents the Rx-Risk index with each comorbidity category mapped to medicines at the ATC classification level using clinical expertise. The mapped index provides a resource for researchers working with health claims data utilising ATC codes or that have mappings to

1
2
3 the ATC codes to calculate comorbidity, based on prescription medicine dispensing's in an
4
5 outpatient population. We have shown that the updated Rx-Risk was highly predictive of
6
7 one-year mortality in both the populations examined and is a valid measure of comorbidity
8
9 in an outpatient population and is therefore likely to be useful in a range of observational
10
11 data settings.
12
13

14
15 All forms of Rx-Risk predicted mortality better than just age and sex alone. The best results
16
17 for predicting one-year mortality were achieved when modelling Rx-Risk as individual
18
19 comorbidities or as a weighted score. The unweighted Rx-Risk score had similar
20
21 performance to simple prescription medicine counts. In practice, Rx-Risk treated as
22
23 individual covariates may be more easily applied, however, the weighted score may be a
24
25 better option when sample sizes are smaller taking up fewer degrees of freedom. Making
26
27 the ATC map available to researchers will facilitate the use of the Rx-Risk in place of
28
29 comorbidity estimated simply by prescription counts.
30
31

32
33
34 Internal and external validation showed that the weighted index was predictive of one-year
35
36 mortality within different subsets of the veteran population and in a general population and
37
38 is likely to be generalizable to other elderly populations.
39
40

41
42 The Rx-Risk index has been updated accounting for the introduction of new medicines to
43
44 the market, making this index a useful resource for researchers. The updated Rx-Risk has 46
45
46 comorbidities, however 3 (tuberculosis, and hepatitis B and C) were removed in the analysis
47
48 stage as there were insufficient cases in the DVA cohort. A younger or larger sample may
49
50 have allowed these comorbidities to be assessed. For consistency, these comorbidities were
51
52 also excluded from the analysis in the PBS cohort despite there being few but sufficient
53
54 cases. The Rx-Risk index has been updated and mapped to ATC codes based on medicine
55
56
57
58
59
60

1
2
3 availability in Australia; hence modifications may be required for use in other health
4
5 systems.
6

7
8 The health care encounter inclusion criteria were not the same for both cohorts. The DVA
9
10 cohort included people with a hospitalisation or GP visit, while the PBS cohort was limited to
11
12 those with a prescription dispensing only. However, the difference across populations is
13
14 small, as 96.7% of the DVA cohort had a medication dispensed in the six month selection
15
16 period.
17

18
19 Including all individual comorbidities as indicator variables may not be appropriate in some
20
21 studies, such as those looking at the effect of a particular treatment on an adverse event
22
23 when the treatment itself is included in the construction of the comorbidity score. For
24
25 example, when determining whether the risk of NSAIDs is associated with gastrointestinal
26
27 bleeds, it would not be correct to adjust for inflammation/pain as an indicator as the
28
29 medicines mapped to this comorbidity include NSAIDs. In this scenario it would be advisable
30
31 to remove inflammation/pain as an indicator or use the weighted Rx-Risk score. Lastly, the
32
33 Rx-Risk category weights derived in this study may not be applicable to younger
34
35 populations. We limited our cohorts to patients over 65 years of age so factors that are
36
37 predictors of mortality in this age group may not be predictors in a younger group. When we
38
39 applied the weights derived in the veteran population to the 10% Australian PBS sample the
40
41 predictive model had a c-statistic of 0.833 which was higher than the c-statistic calculated
42
43 when weights were derived on the 10% sample itself (c-statistic=0.809) but not as good as
44
45 using the individual comorbidity indicators. We suggest the reason for the lower c-statistic
46
47 when using PBS weights in the PBS data is due to the cohort being younger and therefore
48
49 have a lower risk of death. As the c-statistic is calculated based on the predicted
50
51
52
53
54
55
56
57
58
59
60

1
2
3 probabilities and the count of concordant, discordant and tied pairs the c-statistic of 0.809
4
5 suggests the model is less effective in discriminating between those who did die and those
6
7 who didn't.
8
9

10 **Conclusion**

11
12 The updated Rx-Risk index is a valid measure of comorbidity and strongly predicted one-
13
14 year mortality in an outpatient population; irrespective of whether the index was modelled
15
16 as a score or modelled as individual comorbidities. Modelling the Rx-Risk as individual
17
18 covariates rather than an overall score (or count) was most predictive of one-year mortality
19
20 and may be more useful in practice.
21
22
23
24

25 **Contributor statement:**

26 Research area and study design: NP MK ER EER Data acquisition: NP MK JB; data analysis
27 and interpretation: NP MK ER AKC LK; statistical analysis: NP MK; Mapping of the ATC codes
28 to the RxRisk categories; JB LK EER. All authors drafted, edited and approved the final
29 manuscript.
30
31

32 **Competing Interests:**

33 None declared for any author.
34
35

36 **Funding:**

37 This work was funded by the Australian Government Department of Veterans' Affairs (DVA)
38 as part of the Veterans' Medicines Advice and Therapeutics Education Services (Veterans'
39 MATES) program. EER is supported by NHMRC GNT 1110139. DVA reviewed this manuscript
40 before submission but had no role in the design or conduct of this research.
41
42

43 **Data sharing Agreement:**

44 Data are available through the Australian Government Department of Veterans' Affairs
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Caughey, G.E., et al., *Prevalence of comorbidity of chronic diseases in Australia*. BMC Public Health, 2008. **8**: p. 221.
2. Vogeli, C., et al., *Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs*. J Gen Intern Med, 2007. **22 Suppl 3**: p. 391-5.
3. Feinstein, A.R., *The Pre-Therapeutic Classification of Co-Morbidity in Chronic Disease*. J Chronic Dis, 1970. **23**(7): p. 455-68.
4. Von Korff, M., E.H. Wagner, and K. Saunders, *A chronic disease score from automated pharmacy data*. J Clin Epidemiol, 1992. **45**(2): p. 197-203.
5. Clark, D.O., et al., *A chronic disease score with empirically derived weights*. Med Care, 1995. **33**(8): p. 783-95.
6. Sales, A.E., et al., *Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population*. Med Care, 2003. **41**(6): p. 753-60.
7. Johnson, M.L., et al., *Adapting the Rx-Risk-V for mortality prediction in outpatient populations*. Med Care, 2006. **44**(8): p. 793-7.
8. Vitry, A., et al., *Validity of medication-based co-morbidity indices in the Australian elderly population*. Aust N Z J Public Health, 2009. **33**(2): p. 126-30.
9. Lu, C.Y., et al., *Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting*. J Clin Epidemiol, 2011. **64**(2): p. 223-8.
10. Sloan, K.L., et al., *Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument*. Med Care, 2003. **41**(6): p. 761-74.
11. Caughey, G.E., et al., *Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts*. Diabetes Res Clin Pract, 2010. **87**(3): p. 385-93.
12. Elixhauser, A., et al., *Comorbidity measures for use with administrative data*. Med Care, 1998. **36**(1): p. 8-27.
13. Charlson, M.E., et al., *A new method of classifying prognostic comorbidity in longitudinal studies: development and validation*. J Chronic Dis, 1987. **40**(5): p. 373-83.
14. Methodology., W.H.O.C.C.f.D.S. *International language for drug utilisation research*. [cited 2017 March 03]; Available from: www.whocc.no/.
15. Australian Government Department of Health and Ageing. *Schedule of Pharmaceutical Benefits*. 2017 [cited 2017 March 21]; Available from: <http://www.pbs.gov.au/>.
16. Bozdogan, H., *Akaike's Information Criterion and Recent Developments in Information Complexity*. J Math Psychol, 2000. **44**(1): p. 62-91.
17. Pencina, M.J., et al., *Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond*. Stat Med, 2008. **27**(2): p. 157-72; discussion 207-12.
18. Hosmer, D.W., *Applied logistic regression*. 2000, New York ; Chichester: Wiley.

Table 1: List of Rx-Risk comorbidity categories, corresponding Anatomical Therapeutic Chemical (ATC) codes, and score weightings in relation to 1-year mortality risk in DVA and PBS data.

Rx-Risk comorbidity category	ATC codes	DVA Data		PBS Data	
		N (%)	Weights for Rx-Risk score	N (%)	Weights for Rx-Risk score
Alcohol dependency	N07BB01-N07BB99	183 (0.1)	6	137 (0.1)	0
Allergies	R01AC01-R01AD60, R06AD02-R06AX27, R06AB04	16684 (12)	-1	1095 (0.4)	2
Anticoagulants	B01AA03-B01AB06, B01AE07, B01AF01, B01AF02, B01AX05	24863 (18)	1	35456 (12)	1
Antiplatelets	B01AC04-B01AC30	52525 (39)	2	50129 (17)	3
Anxiety	N05BA01-N05BA12, N05BE01	15615 (12)	1	24335 (8)	1
Arrhythmia	C01AA05, C01BA01-C01BD01, C07AA07	14992 (11)	2	19108 (6)	2
Benign prostatic hyperplasia	G04CA01-G04CA99, G04CB01, G04CB02 ^a	9003 (7)	0	11933 (4)	-1
Bipolar disorder	N05AN01	231 (0.2)	-1	670 (0.2)	0
Chronic airways disease	R03AC02-R03DC03, R03DX05	33244 (25)	2	59873 (20)	2
Congestive heart failure	C03DA02-C03DA99, C07AB02 - if PBS ^d item code is 8732N, 8733P, 8734Q, 8735R, C07AB07, C07AG02, C07AB12, C03DA04, (C03CA01-C03CC01 AND C09AA01-C09AX99, C09CA01-C09CX99) ^b	23975 (8)	2	24851 (8)	4

1						
2						
3						
4	Dementia	N06DA02-N06DA04, N06DX01	3868 (3)	2	4090 (1)	4
5						
6						
7	Depression	N06AA01-N06AG02, N06AX03-N06AX11, N06AX13-N06AX18, N06AX21-N06AX26	43354 (32)	2	63864 (21)	2
8						
9						
10						
11						
12	Diabetes	A10AA01-A10BX99	17550 (13)	2	48341 (16)	2
13						
14	Epilepsy	N03AA01-N03AX99	15484 (11)	0	23520 (8)	2
15						
16	Glaucoma	S01EA01-S01EB03, S01EC03-S01EX99	16262 (12)	0	22933 (8)	0
17						
18						
19	Gastroesophageal reflux disease	A02BA01-A02BX05	69358 (51)	0	124740 (41)	1
20						
21						
22						
23	Gout	M04AA01-M04AC01	13723 (10)	1	21700 (7)	0
24						
25	Hepatitis B	J05AF08, J05AF10, J05AF11	7 (0.01)	NA	80 (0.03)	NA
26						
27						
28	Hepatitis C	J05AB54, L03AB10, L03AB11, L03AB60, L03AB61, J05AE14, J05AE11-J05AE12, J05AX14, J05AX15, J05AX65, J05AB04	1 (0.0)	NA	12 (0.0)	NA
29						
30						
31						
32						
33						
34						
35	Human immunodeficiency virus	J05AE01-J05AE10, J05AF12-J05AG05, J05AR01-J05AR99, J05AX07-J05AX09, J05AX12, J05AF01- J05AF07, J05AF09	42 (0.03)	0	120 (0.04)	0
36						
37						
38						
39						
40						
41						
42						
43	Hyperkalaemia	V03AE01	197 (0.2)	4	0 (0)	NA
44						
45	Hyperlipidaemia	A10BH03 ^e , C10AA01- C10BX09	67690 (50)	-1	156214 (52)	-1
46						
47						
48	Hypertension	C03AA01-C03BA11, C03DB01, C03DB99, C03EA01, C09BA02- C09BA09, C09DA02- C09DA08, C02AB01- C02AC05, C02DB02- C02DB99, (C03CA01- C03CC01 OR	71867 (53)	-1	162809 (54)	-1
49						
50						
51						
52						
53						
54						
55						
56						
57						
58						
59						
60						

		C09CA01-C09CX99) ^c				
	Hyperthyroidism	H03BA02, H03BB01	992 (1)	2	1569 (1)	0
	Hypothyroidism	H03AA01-H03AA02	13438 (10)	0	26630 (9)	1
	Irritable bowel syndrome	A07EC01-A07EC04, A07EA01-A07EA02, A07EA06, L04AA33	1132 (1)	0	2586 (1)	-1
	Ischaemic heart disease: angina	C01DA02-C01DA14, C01DX16, C08EX02	16988 (13)	2	19606 (7)	1
	Ischaemic heart disease: hypertension	C07AA01-C07AA06, C07AA08-C07AB01, C07AB02 - if PBS ^d item code is not 8732N, 8733P, 8734Q, 8735R, C07AG01, C08CA01- C08DB01, C09DB01- C09DB04, C09DX01, C09BB02-C09BB10, C07AB03, C09DX03, C10BX03 ^f	49947 (37)	-1	101575 (34)	-1
	Incontinence	G04BD01-G04BD99	5554 (4)	0	6181 (2)	-1
	Inflammation/pain	M01AB01-M01AH06	23510 (17)	-1	60996 (20)	-1
	Liver failure	A06AD11, A07AA11	5034 (4)	3	4701 (2)	4
	Malignancies	L01AA01-L01XX41	7689 (6)	2	7719 (3)	6
	Malnutrition	B05BA01-B05BA10	16 (0.01)	0	19 (0.01)	0
	Migraine	N02CA01-N02CX01	708 (1)	-1	2185 (1)	-1
	Osteoporosis/Page t's	M05BA01-M05BB05, M05BX03, M05BX04, G03XC01, H05AA02	21448 (16)	-1	32338 (11)	0
	Pain	N02AA01-N02AX02, N02AX06, N02AX52, N02BE51	44035 (33)	3	71755 (24)	4
	Pancreatic insufficiency	A09AA02	433 (0.3)	0	930 (0.3)	6
	Parkinsons	N04AA01-N04BX02	4237 (3)	3	6560 (2)	4

1						
2						
3	Psoriasis	D05AA01-D05AA99, D05BB01 D05BB02, D05AX02, D05AC01- D05AC51, D05AX52	1224 (1)	0	2487 (1)	0
4						
5						
6						
7						
8	Psychotic illness	N05AA01-N05AB02, N05AB06-N05AL07, N05AX07-N05AX13	7714 (6)	6	9390 (3)	6
9						
10						
11						
12	Pulmonary hypertension	C02KX01-C02KX05, PBS ^d item code 9547L, 9605M	40 (0.03)	6	45 (0.01)	0
13						
14						
15						
16	Renal disease	B03XA01-B03XA03, A11CC01-A11CC04, V03AE02, V03AE03, V03AE05	1816 (1)	6	2548 (1)	6
17						
18						
19						
20						
21	Smoking cessation	N07BA01-N07BA03, N06AX12	1145 (1)	6	2710 (1)	3
22						
23						
24						
25	Steroid responsive disease	H02AB01-H02AB10	19106 (14)	2	35999 (12)	3
26						
27						
28	Transplant	L04AA06, L04AA10, L04AA18, L04AD01, L04AD02	102 (0.1)	0	368 (0.1)	6
29						
30						
31						
32	Tuberculosis	J04AC01-J04AC51, J04AM01-J04AM99	0	NA	17 (0.01)	NA
33						
34						

^a Benign prostatic hyperplasia medicines are tested for gender - must be male. Females suffering from bladder obstructions can be prescribed medicines used to treat benign prostatic hyperplasia.

^b Must have at least two medicines prescribed with one of those medicines having an Anatomical Therapeutic Chemical (ATC) code from C03CA01–C03CC01 and the other having an ATC code from either C09AA01–C09AX99 or C09CA01–C09CX99

^c Can have medicine dispensed with an ATC code C03CA01–C03CC01 or C09AA01–C09AX99, but not both; as this would indicate chronic heart failure.

^d Pharmaceutical Benefits Scheme

^e Combination product for hyperlipidaemia and diabetes

^f Combination product for hyperlipidaemia and ischaemic heart disease: hypertension

Table 2: Weighting algorithm used to score the Rx-Risk index.*

Odds ratio	P-value	Weighted Rx-Risk score
Any odds ratio	>0.10	0
<1	≤0.10	-1
1.0 ≤ and <1.2	≤0.10	1
1.2 ≤ and <1.4	≤0.10	2
1.4 ≤ and <1.6	≤0.10	3
1.6 ≤ and <1.8	≤0.10	4
1.8 ≤ and <2.0	≤0.10	5
≥2.0	≤0.10	6

*Weights are based on the size of odds ratio quantifying the probability of mortality in an outpatient population within one year, given treatment for a specified comorbidity.

Table 3: Comparison of different Rx-Risk scoring and modelling methods to predict one- year mortality in the DVA and PBS populations.

Models	DVA				PBS			
	AIC ^a	Difference in AIC ^b	C-statistic ^c (95% Confidence Interval)	Relative IDI, p-value	AIC ^a	Difference in AIC ^b	C-statistic ^c (95% Confidence Interval)	Relative IDI, p-value
Base model (BM): age and sex	80538.5	-	0.738 (0.734, 0.742)	-	79527.9	-	0.761 (0.756, 0.766)	-
Rx-Risk measures								
BM + unweighted Rx-Risk	79420.1	1118.4	0.751 (0.747, 0.754)	14.0%, <.0001	77029.9	2498.0	0.796 (0.791, 0.800)	25.5%, <.0001
BM + DVA weighted Rx-Risk	76102.4	4436.1	0.786 (0.782, 0.789)	65.6%, <.0001	73143.8	6384.1	0.833 (0.829, 0.837)	92.0%, <.0001
BM + PBS weighted Rx-Risk	78573.5	1965.0	0.761 (0.757, 0.764)	26.4%, <.0001	75849.6	3678.3	0.809 (0.805, 0.813)	44.0%, <.0001
BM + 43 comorbidity indicators	75692.2	4846.3	0.791 (0.788, 0.795)	73.9%, <.0001	71689.1	7838.8	0.845 (0.842, 0.849)	114.8%, <.0001
Crude measures								
BM + prescription count	79105.9	1432.6	0.755 (0.751, 0.759)	18.6%, <.0001	76762.8	2765.1	0.799 (0.795, 0.804)	31.4%, <.0001
BM + unique ATC ^d medicine count	78374.5	2164.0	0.762 (0.758, 0.766)	29.4%, <.0001	75369.1	4158.8	0.814 (0.810, 0.818)	50.0%, <.0001
BM + unique PBS ^e medicine count	78210.2	2328.3	0.764 (0.760, 0.768)	32.1%, <.0001	75108.8	4419.1	0.816 (0.812, 0.820)	55.8%, <.0001

^a AIC: Akaike information criterion model. The model with the lowest AIC value is considered the best fit.
^b AIC score compared to the AIC score of the base model. A model with a lower score of 10 (or more) is considered superior.
^c Possible range 0-1, with 1 indicating perfect prediction and 0.5 indicating chance prediction. A c-statistic between 0.8–0.9 is generally considered as excellent, and between 0.7–0.8 acceptable.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

^d Anatomical Chemical Therapeutic classification system, count based on the number of unique ATC codes dispensed.

^e Pharmaceutical Benefits Scheme, count based on the number of unique PBS item codes dispensed.

For peer review only

BMJ Open

The validity of the Rx-Risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-021122.R1
Article Type:	Research
Date Submitted by the Author:	11-Feb-2018
Complete List of Authors:	Pratt, Nicole; University of South Australia, Sansom Institute for Health Research Kerr, Mhairi ; University of South Australia, Sansom Institute for Health Research Barratt, John; University of South Australia, Sansom Institute for Health Research Kemp-Casey, Anna; University of South Australia, Sansom Institute for Health Research Kalisch Ellett, Lisa; University of South Australia, Sansom Institute for Health Research Ramsay, Emmae; University of South Australia, Sansom Institute for Health Research Roughead, Elizabeth; University of South Australia, Sansom Institute for Health Research
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	chronic disease burden, comorbidity, mortality prediction, model validation, claims data, weighting

SCHOLARONE™
Manuscripts

Title: The validity of the Rx-Risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system

Authors: Pratt N^a, Kerr M^a, Barratt J^a, Kemp-Casey A^a, Kalisch Ellett L^a, Ramsay E^a, Roughead EE^a.

- a. Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia.

Corresponding Author: Nicole Pratt,

Postal address: Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471, Adelaide, SA 5001, AUSTRALIA.

Email: nicole.pratt@unisa.edu.au

Phone: +618 8302 2818

Nicole Pratt, University of South Australia, Adelaide, Australia

Mhairi Kerr, University of South Australia, Adelaide, Australia

John Barratt, University of South Australia, Adelaide, Australia

Anna Kemp-Casey, University of South Australia, Adelaide, Australia

Lisa Kalisch Ellett, University of South Australia, Adelaide, Australia

Emmae Ramsay, University of South Australia, Adelaide, Australia

Elizabeth Ellen Roughead, University of South Australia, Adelaide, Australia

Key words: chronic disease burden, claims data, comorbidity, weighting, mortality prediction, model validation.

Word Count: 2819

Ethics Statement

This research was approved by the Australian Government Department of Veterans' Affairs (DVA) Human Research Ethics Committee and the University of South Australia Human Research Ethics Committee

1
2
3
4
5
6
7
8
9
10 **Abstract (300 words allowed)**

11 **Objectives:** To provide a map of Anatomical Therapeutic Chemical (ATC) classification
12 system codes to individual Rx-Risk comorbidities and to validate the Rx-Risk comorbidity
13 index.
14

15
16
17
18 **Design:** The 46 comorbidities in the Rx-Risk index were mapped to dispensing's indicative of
19 each condition using ATC codes. Prescription dispensing claims in 2014 were used to
20 calculate the Rx-Risk. A baseline logistic regression model was fitted using age and gender as
21 covariates. Rx-risk was added to the base model as an (i) unweighted score, (ii) weighted
22 score, and as (iii) individual comorbidity categories indicating the presence or absence of
23 each condition. The Akaike information criterion (AIC) and c-statistic were used to compare
24 the models.
25
26
27
28
29
30
31
32
33

34
35 **Setting:** Models were developed in the Australian Government Department of Veterans'
36 Affairs health claims data and external validation was undertaken in a 10% sample of the
37 Australian Pharmaceutical Benefits Scheme Data.
38
39
40

41
42 **Participants:** Subjects aged 65 years or older
43

44 **Outcome measures:** Death within one year (eg 2015)
45

46 **Results:** Compared to the base model (c-statistic 0.738, 95% Confidence Interval (CI) 0.734-
47 0.742), including Rx-Risk improved prediction of mortality; unweighted score 0.751, 95%CI
48 0.747-0.754, weighted score 0.786, 95%CI 0.782-0.789 and individual comorbidities 0.791,
49 95%CI 0.788-0.795. External validation confirmed the utility of the weighted index (c-
50 statistic=0.833).
51
52
53
54
55
56
57
58
59
60

1
2
3 Conclusions: The updated Rx-Risk comorbidity score was predictive of one-year mortality
4
5 and may be useful in practice to adjust for confounding in observational studies using
6
7 medication claims data.
8
9

10
11
12
13
14 **Strength and Limitations of this study (5 bullet points that relate to methods. No results)**
15

16 Strengths

- 17 • This study provides an up to date list of medicines identified by ATC codes mapped
18 to individual Rx-Risk categories
- 19 • Rx-Risk mapped to ATC codes can be easily adapted for use in other health systems
20 making this index a useful resource for researchers worldwide

21
22
23
24
25
26
27
28 Limitations

- 29 • The Rx-Risk index has been updated and mapped to ATC codes based on medicine
30 availability in Australia; hence modifications may be required for use in other health
31 systems
- 32 • This study was limited to patients over 65 years of age so Rx-Risk category weights
33 derived in this study may not be applicable to younger populations.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The prevalence of multimorbidity in the population is increasing [1, 2] and patients with multiple conditions are at greater risk of adverse outcomes [3]. In observational studies, in which the aim is to determine the association between medicine use and adverse events, adjustment for multimorbidity is required to avoid biased results. Reliable methods for identifying and controlling for multiple comorbidities are required in order to make valid comparisons between treatments. The Rx-Risk is a measure for determining an individual's current comorbidities based on their prescription medicine dispensing [4, 5]. It was initially developed for predicting costs of health care [6] and was subsequently adapted to predict mortality in outpatient populations [7, 8]. Rx-Risk has been found to be a better predictor of one- and three-year mortality (one-year mortality: weighted Rx-Risk c-statistic=0.728, 95% CI=0.723-0.733, three-year mortality: 0.731, 95%CI=0.728-0.734) compared to simple prescription counts in the same time periods (one-year mortality: 0.715, 95%CI=0.710-0.720, three-year mortality: 0.718, 95%CI=0.715- 0.721) [9].

The first pharmacy based measure of comorbidity, developed in 1992, was The Chronic Disease Score (CDS) [4], consisting of 17 comorbidity categories. The CDS was subsequently updated and renamed in 2003 as the Rx-Risk-V index, consisting of 45 categories of comorbidity [10]. The Rx-Risk-V index was then adapted to only include comorbidities for which a medicine could be prescribed and therefore could be applied to prescription claims data resulting in an index based on 42 categories of comorbidity [11]. Due to continual advances in pharmaceutical disease management and as new medicines are used to treat particular diseases, e.g. treatment for hepatitis B and C, the Rx-Risk requires periodical

1
2
3 updating and re-validation. A list of Rx-Risk comorbidities and their corresponding medicines
4 mapped to a standardised international coding system has not been published previously
5 and would facilitate use of the index across health systems. Other comorbidity scores such
6 as the Elixhauser and Charlson Index [12, 13] require diagnostic information in their
7 construction. The advantage of the RxRisk is that it requires prescription data only and
8 provides researchers with the ability to measure comorbidity even in a predominately
9 outpatient setting.
10
11

12 The aim of this study was to facilitate the use of the RxRisk in practice by providing a list of
13 the individual RxRisk categories mapped, using clinical expertise, to the World Health
14 Organisation's Anatomical Therapeutic Chemical (ATC) classification system [14] and to
15 determine the validity of the Rx-Risk index, in predicting one-year mortality in an outpatient
16 population.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **Method**

36 **Rx-Risk index mapping**

37
38
39 The Rx-Risk index consists of 46 comorbidity categories. For each Rx-Risk category,
40 medicines indicative of that condition were mapped (see Table 1). This mapping was
41 performed at the ATC classification level and performed by consensus between two
42 pharmacists. If an individual had ≥ 1 dispensing for a medicine in a given category then they
43 were considered to have been treated (using medicines) for that comorbidity. Medications
44 in both the DVA and PBS datasets are coded using the World Health Organisation
45 anatomical therapeutic chemical (ATC) classification system [14] and PBS item codes [15].
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data sources

The primary data source was the Australian Government Department of Veterans' Affairs (DVA's) administrative claims database. This database contains details of all prescription medicines, medical and allied health services, and hospitalisations subsidised by DVA. The current treatment population consists of 223,181 members of the Australian veteran community, which includes veterans, war widows and widowers. The median age of the DVA treatment population is 75 years and 62% are men. DVA also maintains a client file containing gender, date of birth and date of death information.

External validation of the Rx-Risk index was conducted using the Pharmaceutical Benefits Scheme (PBS) 10% sample of the Australian population. This dataset contains information on the dispensing of prescription medicines, and includes basic demographic information regarding gender, year of birth and year of death. It is maintained by the Australian Government Department of Human Services. The current treatment population consists of 1,346,340 members of the Australian community. The median age of the PBS treatment population is 43 years and 48% are men.

Study population

The DVA study population included individuals with at least one health care encounter in the six month period from 1 July 2013 to 31 December 2013. A health care encounter included any of the following: a medication dispensing, a doctor's visit, or hospitalisation. Analysis was restricted to veterans who were DVA Gold Card holders prior to 1 July 2013 (ensuring they were eligible for all DVA subsidised services, thus the data set captured all their health claims), and were between the ages of 65 and 100 years at 1 January 2015 (N=135,406). Inclusion criteria for the PBS cohort were people with a health care encounter

(defined as at least one medicine dispensing) in the six month period from 1 July 2013 to 31 December 2013, who were aged between 65 and 100 years at 1 January 2015 (N=303,135).

The primary outcome for this study was death recorded in 2015, hence patients were only included if they were alive as at 1 January 2015. Rx-Risk scores were calculated separately in each dataset using prescription claims for supplied medicines over a one-year baseline period between 1 January 2014 and 31 December 2014.

Calculating Rx-Risk scores and prescription counts

The full Rx-Risk index has 46 comorbidity categories; however, tuberculosis, and hepatitis B and C were removed from the Rx-Risk index for this study as the number of individuals with these conditions in the DVA cohort was less than 10 so weights could not be generated. This resulted in 43 categories in the validation study. The following forms of the Rx-Risk score were generated. The unweighted Rx-Risk score was calculated as the count of the number of different comorbidity categories for which an individual was treated with a possible score ranging from 0 to 43. The weighted Rx-Risk score was calculated by adding the 43 indicator variables to a logistic regression model with mortality as the outcome including age and gender as covariates. From this model each comorbidity category was assigned a weight according to the statistical significance and magnitude of the odds ratio generated from the logistic regression model (Table 2)[7]. The weighted Rx-Risk score for an individual was then the sum of the weighted indicator variables. As an example, the unweighted RxRisk score for a patient who has two comorbidities 'Pain' and 'Renal disease' is 2, while their weighted Rx Score is 9 that is the sum of the weight for 'Pain' (3) and 'Renal Disease' (6).

[Insert Table 2 here]

1
2
3 Three crude prescription counts were also calculated: (i) total number of prescriptions
4 dispensed in the baseline period (1 January 2014 – 31 December 2014), (ii) total number of
5 unique medicines dispensed in the baseline period based on ATC codes, and (iii) total
6 number of unique medicines dispensed during the baseline period based on PBS item
7 codes[15]. The distinction between ATC and PBS codes was made because different
8 strengths or formulations of the same medicine have the same ATC code but different PBS
9 codes; e.g. if a patient is dispensed two different strengths of the same medicine, this will be
10 counted once in the total number of ATC medicines dispensed but twice in the total number
11 of PBS medicines dispensed.
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **Statistical analysis**

27
28 Primary analysis was performed in the DVA database. A baseline logistic regression model
29 was calculated for mortality using age and gender as predictors. The comorbidity scores,
30 individual comorbidities, and crude prescription counts were added to the baseline model
31 separately. Age, comorbidity scores and crude prescription measures were included in the
32 models as continuous variables assuming linear associations. Models using the individual
33 comorbidities were developed with an indicator variable included for the presence (1) or
34 absence (0) of each individual RxRisk category. The overall goodness-of-fit of each model
35 was compared to the baseline model using the Akaike Information criterion (AIC)[16]. The
36 model with the lowest AIC value is considered the best fit. The difference between the AIC
37 values of two models must be greater than 10 for one model to be considered superior to
38 the other. Model discrimination was compared based on the c-statistic and the relative
39 Integrated Discrimination Improvement (IDI) [17]. The value of the c-statistic can range
40 from 0 to 1, with 1 indicating perfect prediction and 0.5 indicating chance predictions. A c-
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 statistic between 0.8–0.9 is generally considered as excellent, and between 0.7–0.8
4 acceptable[18]. Using 1000 bootstrap samples 95% confidence intervals were calculated for
5 the c-statistics[9].
6
7
8
9

10 11 12 **Internal validation of weighted scores**

13
14 We used 10-fold cross-validation to internally validate the binary logistic regression model
15 used to calculate the Rx-Risk category weights. This subsets the DVA cohort, using random
16 sampling without replacement, into 10 equal folds. Each fold is a 10% subset of the DVA
17 cohort. The training set consisted of 9 folds and was used to calculate Rx-Risk category
18 weights. The calculated weights were then applied to the testing set (i.e. fold left out of
19 training set). A binary logistic regression model of one- year mortality including age, gender
20 and weighted Rx-Risk was built separately for the training set and testing set and the c-
21 statistics recorded. This process was repeated ten times until each fold was used as the
22 testing set once. This resulted in 20 c-statistics being calculated, 10 each on the training and
23 testing set. The average c-statistic was recorded for each set.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Sensitivity analyses**

41
42 Two sensitivity analyses were carried out. In the first sensitivity analysis we used the lower
43 confidence limit of the odds ratio to determine the Rx-Risk category weights rather than the
44 estimated odds ratio itself. We did this as some comorbidities are uncommon in this
45 population resulting in large confidence intervals. In the second sensitivity analysis we
46 calculated the Rx-Risk category weights (based on the odds ratio) generated from 5000
47 bootstrap samples. For each Rx-Risk category the weight was calculated as the median of
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the 5000 weights for that category generated in each bootstrap sample. We did this
4
5 sensitivity analysis to test the stability of the weights.
6
7

8 9 **External Validation**

10
11 To determine the external validity of the weights, the calculated Rx-Risk category weights
12
13 derived from the DVA dataset were applied to the PBS cohort. The Akaike information
14
15 criterion model fit and c-statistics were calculated to determine the validity of the model.
16
17

18 19 **Results**

20
21 Table 1 presents the ATC mapped Rx-Risk categories, derived empirical weights, and
22
23 number of treated individuals in the DVA populations. The most frequent comorbidities
24
25 identified by the Rx-Risk index in the DVA cohort were hypertension (53%), gastro-
26
27 oesophageal reflux disease (GORD) (51%), hyperlipidaemia (50%), and conditions treated
28
29 with antiplatelets (39%). In the DVA cohort of 135,406 people, with a mean age of 83 years
30
31 (standard deviation (SD) 9.5) and 47% were men. The median unweighted Rx-Risk score was
32
33 5 (interquartile range (IQR) 3-7) and the median weighted Rx-Risk score was 3 (0-6).
34
35
36
37

38
39 The baseline model, comprising only age and gender, predicted one-year mortality
40
41 moderately well in the DVA cohort (c-statistic=0.738, 95% Confidence Interval (CI) 0.734-
42
43 0.742). The addition of Rx-Risk to the model increased the performance of the model:
44
45 unweighted Rx-Risk c-statistic=0.751, (95% CI 0.747-0.754), IDI=14.0%, p-value<.0001;
46
47 weighted Rx-Risk c-statistic=0.786, (95% CI=0.782-0.789), IDI=65.6%, p-value<.0001; 43
48
49 individual comorbidities c-statistic=0.791, (95% CI=0.788-0.795), IDI=73.9%, p-value<.0001.
50
51
52

53
54 The model including the 43 comorbidity indicator variables had the lowest AIC (75692),
55
56
57
58
59

1
2
3 highest c-statistic (0.791), and the highest discrimination improvement (73.9%). The models
4 including the weighted Rx-Risk score or 43 comorbidity measures were better predictors of
5 one-year mortality than any of the crude prescription measures (Table 3). Results of the
6 internal 10-fold cross validation were consistent with the main analysis with an average c-
7 statistic of 0.785 achieved over the 10 testing datasets compared to a c-statistic of 0.786 in
8 the primary analysis.
9
10
11
12
13
14
15

16
17 *[Insert Table 3 here]*
18
19
20

21 In the sensitivity analysis using the lower 95% confidence interval limit in the weighting
22 algorithm we found a very similar performance with a c-statistic of 0.787 compared to the
23 weighting algorithm using the estimated odds ratio (c-statistic 0.786). In the second
24 sensitivity analysis in which the weights were calculated from 5000 bootstrap samples we
25 found a similar c-statistic (0.786) compared to the primary analysis.
26
27
28
29
30
31
32
33
34

35 The PBS cohort consisted of 303,135 people, with an mean age of 75 years (standard
36 deviation (SD) 7.4) and 45% were men. Similar to the DVA cohort, the most frequent
37 comorbidities identified by the Rx-Risk index in the PBS cohort were hypertension (54%),
38 hyperlipidaemia (52%) and gastro-oesophageal reflux disease (GORD) (41%). When the DVA
39 derived Rx-risk category weights were applied to the PBS population we found a c-statistic
40 of 0.833 (Table 3) showing good external validity.
41
42
43
44
45
46
47
48
49
50

51 **Discussion**

52 This paper presents the Rx-Risk index with each comorbidity category mapped to medicines
53 at the ATC classification level using clinical expertise. The mapped index provides a resource
54
55
56
57
58
59
60

1
2
3 for researchers working with health claims data utilising ATC codes or that have mappings to
4
5 the ATC codes to calculate comorbidity, based on prescription medicine dispensing's in an
6
7 outpatient population. We have shown that the updated Rx-Risk was highly predictive of
8
9 one-year mortality in both the populations examined and is a valid measure of comorbidity
10
11 in an outpatient population and is therefore likely to be useful in a range of observational
12
13 data settings.
14
15

16
17 All forms of Rx-Risk predicted mortality better than just age and sex alone. The best results
18
19 for predicting one-year mortality were achieved when modelling Rx-Risk as individual
20
21 comorbidities or as a weighted score. The unweighted Rx-Risk score had similar
22
23 performance to simple prescription medicine counts. Internal and external validation
24
25 showed that the weighted index was predictive of one-year mortality within the veteran
26
27 population and show good external validity when applied to a general population setting.
28
29 These results suggest that the weighted RxRisk score is likely to be generalizable to other
30
31 populations. Making the ATC map available to researchers will facilitate the use of the Rx-
32
33 Risk in place of comorbidity estimated simply by prescription counts.
34
35
36

37
38 The Rx-Risk index has been updated accounting for the introduction of new medicines to
39
40 the market, making this index a useful resource for researchers. The updated Rx-Risk has 46
41
42 comorbidities, however 3 (tuberculosis, and hepatitis B and C) were removed in the analysis
43
44 stage as there were insufficient cases in the DVA cohort. A younger or larger sample may
45
46 have allowed these comorbidities to be assessed. For consistency, these comorbidities were
47
48 also excluded from the analysis in the PBS cohort despite there being few but sufficient
49
50 cases. The Rx-Risk index has been updated and mapped to ATC codes based on medicine
51
52
53
54
55
56
57
58
59
60

1
2
3 availability in Australia; hence modifications may be required for use in other health
4
5 systems.
6

7
8 The health care encounter inclusion criteria were not the same for both cohorts. The DVA
9
10 cohort included people with a hospitalisation or GP visit, while the PBS cohort was limited to
11
12 those with a prescription dispensing only. However, the difference across populations is
13
14 small, as 96.7% of the DVA cohort had a medication dispensed in the six month selection
15
16 period.
17

18
19 Comorbidity scores are often used in observational studies to reduce the potential for
20
21 confounding. The advantage of these summary scores is that they simplify the inclusion of
22
23 individual covariates for each comorbidity into a single summary score. This is a particular
24
25 advantage when sample sizes are small or the outcome under study is rare. Our analysis
26
27 demonstrated that the performance of the weighted RxRisk score performed as well as the
28
29 model which included each individual comorbidity category. Additionally, including all
30
31 individual comorbidities as indicator variables may not be appropriate in some studies, such
32
33 as those looking at the effect of a particular treatment on an adverse event when the
34
35 treatment itself is included in the construction of the comorbidity score. For example, when
36
37 determining whether the risk of NSAIDs is associated with gastrointestinal bleeds, it would
38
39 not be correct to adjust for inflammation/pain as an indicator as the medicines mapped to
40
41 this comorbidity include NSAIDs. In this scenario it would be advisable to remove
42
43 inflammation/pain as an indicator or use the weighted Rx-Risk score. Lastly, although the
44
45 weighted RxRisk score performed well in the PBS data set, which suggests that the weights
46
47 have a good external validity, the Rx-Risk category weights derived in this study may not be
48
49 applicable to all external populations. We limited our cohorts to patients over 65 years of
50
51
52
53
54
55
56
57
58
59
60

1
2
3 age so factors that are predictors of mortality in this age group may not be predictors in a
4
5 younger group.
6
7

8 **Conclusion**

9
10 The updated Rx-Risk comorbidity score is a valid measure of comorbidity and strongly
11
12 predicted one-year mortality in an outpatient population. The weighted Rx-Risk score was
13
14 found to be valid in an external population and may be useful in practice to adjust for
15
16 confounding in observational studies using medication claims data.
17
18

19 **Contributor statement:**

20
21 Research area and study design: NP MK ER EER Data acquisition: NP MK JB; data analysis
22
23 and interpretation: NP MK ER AKC LK; statistical analysis: NP MK; Mapping of the ATC codes
24
25 to the RxRisk categories; JB LK EER. All authors drafted, edited and approved the final
26
27 manuscript.

28 **Competing Interests:**

29
30 None declared for any author.

31 **Funding:**

32
33 This work was funded by the Australian Government Department of Veterans' Affairs (DVA)
34
35 as part of the Veterans' Medicines Advice and Therapeutics Education Services (Veterans'
36
37 MATES) program. EER is supported by NHMRC GNT 1110139. DVA reviewed this manuscript
38
39 before submission but had no role in the design or conduct of this research.

40 **Data sharing Agreement:**

41
42 Data are available through the Australian Government Department of Veterans' Affairs
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Caughey, G.E., et al., *Prevalence of comorbidity of chronic diseases in Australia*. BMC Public Health, 2008. **8**: p. 221.
2. Vogeli, C., et al., *Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs*. J Gen Intern Med, 2007. **22 Suppl 3**: p. 391-5.
3. Feinstein, A.R., *The Pre-Therapeutic Classification of Co-Morbidity in Chronic Disease*. J Chronic Dis, 1970. **23**(7): p. 455-68.
4. Von Korff, M., E.H. Wagner, and K. Saunders, *A chronic disease score from automated pharmacy data*. J Clin Epidemiol, 1992. **45**(2): p. 197-203.
5. Clark, D.O., et al., *A chronic disease score with empirically derived weights*. Med Care, 1995. **33**(8): p. 783-95.
6. Sales, A.E., et al., *Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population*. Med Care, 2003. **41**(6): p. 753-60.
7. Johnson, M.L., et al., *Adapting the Rx-Risk-V for mortality prediction in outpatient populations*. Med Care, 2006. **44**(8): p. 793-7.
8. Vitry, A., et al., *Validity of medication-based co-morbidity indices in the Australian elderly population*. Aust N Z J Public Health, 2009. **33**(2): p. 126-30.
9. Lu, C.Y., et al., *Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting*. J Clin Epidemiol, 2011. **64**(2): p. 223-8.
10. Sloan, K.L., et al., *Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument*. Med Care, 2003. **41**(6): p. 761-74.
11. Caughey, G.E., et al., *Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts*. Diabetes Res Clin Pract, 2010. **87**(3): p. 385-93.
12. Elixhauser, A., et al., *Comorbidity measures for use with administrative data*. Med Care, 1998. **36**(1): p. 8-27.
13. Charlson, M.E., et al., *A new method of classifying prognostic comorbidity in longitudinal studies: development and validation*. J Chronic Dis, 1987. **40**(5): p. 373-83.
14. Methodology., W.H.O.C.C.f.D.S. *International language for drug utilisation research*. [cited 2017 March 03]; Available from: www.whocc.no/.
15. Australian Government Department of Health and Ageing. *Schedule of Pharmaceutical Benefits*. 2017 [cited 2017 March 21]; Available from: <http://www.pbs.gov.au/>.
16. Bozdogan, H., *Akaike's Information Criterion and Recent Developments in Information Complexity*. J Math Psychol, 2000. **44**(1): p. 62-91.
17. Pencina, M.J., et al., *Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond*. Stat Med, 2008. **27**(2): p. 157-72; discussion 207-12.
18. Hosmer, D.W., *Applied logistic regression*. 2000, New York ; Chichester: Wiley.

Table 1: List of Rx-Risk comorbidity categories, corresponding Anatomical Therapeutic Chemical (ATC) codes, and score weightings in relation to 1-year mortality risk in DVA and PBS data.

Rx-Risk comorbidity category	ATC codes	DVA Data	
		N (%)	Weights for Rx-Risk score
Alcohol dependency	N07BB01-N07BB99	183 (0.1)	6
Allergies	R01AC01-R01AD60, R06AD02-R06AX27, R06AB04	16684 (12)	-1
Anticoagulants	B01AA03-B01AB06, B01AE07, B01AF01, B01AF02, B01AX05	24863 (18)	1
Antiplatelets	B01AC04-B01AC30	52525 (39)	2
Anxiety	N05BA01-N05BA12, N05BE01	15615 (12)	1
Arrhythmia	C01AA05, C01BA01-C01BD01, C07AA07	14992 (11)	2
Benign prostatic hyperplasia	G04CA01-G04CA99, G04CB01, G04CB02 ^a	9003 (7)	0
Bipolar disorder	N05AN01	231 (0.2)	-1
Chronic airways disease	R03AC02-R03DC03, R03DX05	33244 (25)	2
Congestive heart failure	C03DA02-C03DA99, C07AB02 - if PBS ^d item code is 8732N, 8733P, 8734Q, 8735R, C07AB07, C07AG02, C07AB12, C03DA04, (C03CA01-C03CC01 AND C09AA01-C09AX99, C09CA01-C09CX99) ^b	23975 (8)	2

1				
2				
3	Dementia	N06DA02-N06DA04, N06DX01	3868 (3)	2
4				
5				
6	Depression	N06AA01-N06AG02, N06AX03-N06AX11, N06AX13-N06AX18, N06AX21-N06AX26	43354 (32)	2
7				
8				
9				
10				
11	Diabetes	A10AA01-A10BX99	17550 (13)	2
12				
13	Epilepsy	N03AA01-N03AX99	15484 (11)	0
14				
15	Glaucoma	S01EA01-S01EB03, S01EC03-S01EX99	16262 (12)	0
16				
17				
18	Gastroesophageal reflux disease	A02BA01-A02BX05	69358 (51)	0
19				
20				
21	Gout	M04AA01-M04AC01	13723 (10)	1
22				
23	Hepatitis B	J05AF08, J05AF10, J05AF11	7 (0.01)	NA
24				
25				
26				
27	Hepatitis C	J05AB54, L03AB10, L03AB11, L03AB60, L03AB61, J05AE14, J05AE11-J05AE12, J05AX14, J05AX15, J05AX65, J05AB04	1 (0.0)	NA
28				
29				
30				
31				
32				
33				
34	Human immunodeficiency virus	J05AE01-J05AE10, J05AF12-J05AG05, J05AR01-J05AR99, J05AX07-J05AX09, J05AX12, J05AF01- J05AF07, J05AF09	42 (0.03)	0
35				
36				
37				
38				
39				
40				
41	Hyperkalaemia	V03AE01	197 (0.2)	4
42				
43	Hyperlipidaemia	A10BH03 ^e , C10AA01- C10BX09	67690 (50)	-1
44				
45				
46				
47	Hypertension	C03AA01-C03BA11, C03DB01, C03DB99, C03EA01, C09BA02- C09BA09, C09DA02- C09DA08, C02AB01- C02AC05, C02DB02- C02DB99, (C03CA01- C03CC01 OR C09CA01-C09CX99) ^c	71867 (53)	-1
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1				
2				
3				
4	Hyperthyroidism	H03BA02, H03BB01	992 (1)	2
5				
6	Hypothyroidism	H03AA01-H03AA02	13438 (10)	0
7				
8	Irritable bowel syndrome	A07EC01-A07EC04, A07EA01-A07EA02, A07EA06, L04AA33	1132 (1)	0
9				
10				
11				
12	Ischaemic heart disease: angina	C01DA02-C01DA14, C01DX16, C08EX02	16988 (13)	2
13				
14				
15	Ischaemic heart disease: hypertension	C07AA01-C07AA06, C07AA08-C07AB01, C07AB02 - if PBS ^d item code is not 8732N, 8733P, 8734Q, 8735R, C07AG01, C08CA01- C08DB01, C09DB01- C09DB04, C09DX01, C09BB02-C09BB10, C07AB03, C09DX03, C10BX03 ^f	49947 (37)	-1
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29	Incontinence	G04BD01-G04BD99	5554 (4)	0
30				
31	Inflammation/pain	M01AB01-M01AH06	23510 (17)	-1
32				
33	Liver failure	A06AD11, A07AA11	5034 (4)	3
34				
35	Malignancies	L01AA01-L01XX41	7689 (6)	2
36				
37	Malnutrition	B05BA01-B05BA10	16 (0.01)	0
38				
39	Migraine	N02CA01-N02CX01	708 (1)	-1
40				
41				
42	Osteoporosis/Page t's	M05BA01-M05BB05, M05BX03, M05BX04, G03XC01, H05AA02	21448 (16)	-1
43				
44				
45				
46	Pain	N02AA01-N02AX02, N02AX06, N02AX52, N02BE51	44035 (33)	3
47				
48				
49				
50	Pancreatic insufficiency	A09AA02	433 (0.3)	0
51				
52				
53	Parkinsons	N04AA01-N04BX02	4237 (3)	3
54				
55	Psoriasis	D05AA01-D05AA99,	1224 (1)	0
56				
57				
58				
59				
60				

		D05BB01 D05BB02, D05AX02, D05AC01- D05AC51, D05AX52		
	Psychotic illness	N05AA01-N05AB02, N05AB06-N05AL07, N05AX07-N05AX13	7714 (6)	6
	Pulmonary hypertension	C02KX01-C02KX05, PBS ^d item code 9547L, 9605M	40 (0.03)	6
	Renal disease	B03XA01-B03XA03, A11CC01-A11CC04, V03AE02, V03AE03, V03AE05	1816 (1)	6
	Smoking cessation	N07BA01-N07BA03, N06AX12	1145 (1)	6
	Steroid responsive disease	H02AB01-H02AB10	19106 (14)	2
	Transplant	L04AA06, L04AA10, L04AA18, L04AD01, L04AD02	102 (0.1)	0
	Tuberculosis	J04AC01-J04AC51, J04AM01-J04AM99	0	NA

^a Benign prostatic hyperplasia medicines are tested for gender - must be male. Females suffering from bladder obstructions can be prescribed medicines used to treat benign prostatic hyperplasia.

^b Must have at least two medicines prescribed with one of those medicines having an Anatomical Therapeutic Chemical (ATC) code from C03CA01–C03CC01 and the other having an ATC code from either C09AA01–C09AX99 or C09CA01–C09CX99

^c Can have medicine dispensed with an ATC code C03CA01–C03CC01 or C09AA01–C09AX99, but not both; as this would indicate chronic heart failure.

^d Pharmaceutical Benefits Scheme

^e Combination product for hyperlipidaemia and diabetes

^f Combination product for hyperlipidaemia and ischaemic heart disease: hypertension

Table 2: Weighting algorithm used to score the Rx-Risk index.*

Odds ratio	P-value	Weighted Rx-Risk score
Any odds ratio	>0.10	0
<1	≤0.10	-1
1.0 ≤ and <1.2	≤0.10	1
1.2 ≤ and <1.4	≤0.10	2
1.4 ≤ and <1.6	≤0.10	3
1.6 ≤ and <1.8	≤0.10	4
1.8 ≤ and <2.0	≤0.10	5
≥2.0	≤0.10	6

*Weights are based on the size of odds ratio quantifying the probability of mortality in an outpatient population within one year, given treatment for a specified comorbidity.

Table 3: Comparison of different Rx-Risk scoring and modelling methods to predict one- year mortality in the DVA population and external validation using the PBS population.

Models	DVA				PBS			
	AIC ^a	Difference in AIC ^b	C-statistic ^c (95% Confidence Interval)	Relative IDI, p-value	AIC ^a	Difference in AIC ^b	C-statistic ^c (95% Confidence Interval)	Relative IDI, p-value
Base model (BM): age and sex	80538.5	-	0.738 (0.734, 0.742)	-	79527.9	-	0.761 (0.756, 0.766)	-
Rx-Risk measures								
BM + unweighted Rx-Risk	79420.1	1118.4	0.751 (0.747, 0.754)	14.0%, <.0001	77029.9	2498.0	0.796 (0.791, 0.800)	25.5%, <.0001
BM + DVA weighted Rx-Risk	76102.4	4436.1	0.786 (0.782, 0.789)	65.6%, <.0001	73143.8	6384.1	0.833 (0.829, 0.837)	92.0%, <.0001
BM + 43 comorbidity indicators	75692.2	4846.3	0.791 (0.788, 0.795)	73.9%, <.0001	71689.1	7838.8	0.845 (0.842, 0.849)	114.8%, <.0001
Crude measures								
BM + prescription count	79105.9	1432.6	0.755 (0.751, 0.759)	18.6%, <.0001	76762.8	2765.1	0.799 (0.795, 0.804)	31.4%, <.0001
BM + unique ATC ^d medicine count	78374.5	2164.0	0.762 (0.758, 0.766)	29.4%, <.0001	75369.1	4158.8	0.814 (0.810, 0.818)	50.0%, <.0001
BM + unique PBS Item Code ^e medicine count	78210.2	2328.3	0.764 (0.760, 0.768)	32.1%, <.0001	75108.8	4419.1	0.816 (0.812, 0.820)	55.8%, <.0001

^a AIC: Akaike information criterion model. The model with the lowest AIC value is considered the best fit.

^b AIC score compared to the AIC score of the base model. A model with a lower score of 10 (or more) is considered superior.

- 1
2
3
4
5 ^c Possible range 0-1, with 1 indicating perfect prediction and 0.5 indicating chance prediction. A c-statistic between 0.8–0.9 is generally
6 considered as excellent, and between 0.7–0.8 acceptable.
7 ^d Anatomical Chemical Therapeutic classification system, count based on the number of unique ATC codes dispensed.
8 ^e Pharmaceutical Benefits Scheme, count based on the number of unique PBS item codes dispensed.
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

BMJ Open

The validity of the Rx-Risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-021122.R2
Article Type:	Research
Date Submitted by the Author:	15-Mar-2018
Complete List of Authors:	Pratt, Nicole; University of South Australia, Sansom Institute for Health Research Kerr, Mhairi ; University of South Australia, Sansom Institute for Health Research Barratt, John; University of South Australia, Sansom Institute for Health Research Kemp-Casey, Anna; University of South Australia, Sansom Institute for Health Research Kalisch Ellett, Lisa; University of South Australia, Sansom Institute for Health Research Ramsay, Emmae; University of South Australia, Sansom Institute for Health Research Roughead, Elizabeth; University of South Australia, Sansom Institute for Health Research
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	chronic disease burden, comorbidity, mortality prediction, model validation, claims data, weighting

SCHOLARONE™
Manuscripts

Title: The validity of the Rx-Risk comorbidity index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) classification system

Authors: Pratt N^a, Kerr M^a, Barratt J^a, Kemp-Casey A^a, Kalisch Ellett L^a, Ramsay E^a, Roughead EE^a.

- a. Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia.

Corresponding Author: Nicole Pratt,

Postal address: Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471, Adelaide, SA 5001, AUSTRALIA.

Email: nicole.pratt@unisa.edu.au

Phone: +618 8302 2818

Nicole Pratt, University of South Australia, Adelaide, Australia

Mhairi Kerr, University of South Australia, Adelaide, Australia

John Barratt, University of South Australia, Adelaide, Australia

Anna Kemp-Casey, University of South Australia, Adelaide, Australia

Lisa Kalisch Ellett, University of South Australia, Adelaide, Australia

Emmae Ramsay, University of South Australia, Adelaide, Australia

Elizabeth Ellen Roughead, University of South Australia, Adelaide, Australia

Key words: chronic disease burden, claims data, comorbidity, weighting, mortality prediction, model validation.

Word Count: 2819

Ethics Statement

This research was approved by the Australian Government Department of Veterans' Affairs (DVA) Human Research Ethics Committee and the University of South Australia Human Research Ethics Committee

Abstract (300 words allowed)

Objectives: To provide a map of Anatomical Therapeutic Chemical (ATC) classification system codes to individual Rx-Risk comorbidities and to validate the Rx-Risk comorbidity index.

Design: The 46 comorbidities in the Rx-Risk index were mapped to dispensing's indicative of each condition using ATC codes. Prescription dispensing claims in 2014 were used to calculate the Rx-Risk. A baseline logistic regression model was fitted using age and gender as covariates. Rx-risk was added to the base model as an (i) unweighted score, (ii) weighted score, and as (iii) individual comorbidity categories indicating the presence or absence of each condition. The Akaike information criterion (AIC) and c-statistic were used to compare the models.

Setting: Models were developed in the Australian Government Department of Veterans' Affairs health claims data and external validation was undertaken in a 10% sample of the Australian Pharmaceutical Benefits Scheme Data.

Participants: Subjects aged 65 years or older

Outcome measures: Death within one year (eg 2015)

Results: Compared to the base model (c-statistic 0.738, 95% Confidence Interval (CI) 0.734-0.742), including Rx-Risk improved prediction of mortality; unweighted score 0.751, 95%CI 0.747-0.754, weighted score 0.786, 95%CI 0.782-0.789 and individual comorbidities 0.791, 95%CI 0.788-0.795. External validation confirmed the utility of the weighted index (c-statistic=0.833).

Conclusions: The updated Rx-Risk comorbidity score was predictive of one-year mortality and may be useful in practice to adjust for confounding in observational studies using medication claims data.

1
2
3
4
5
6
7
8 **Strength and Limitations of this study (5 bullet points that relate to methods. No results)**

9
10 Strengths

- 11
- 12 • This study provides an up to date list of medicines identified by ATC codes mapped
 - 13 to individual Rx-Risk categories
 - 14
 - 15
 - 16 • Rx-Risk mapped to ATC codes can be easily adapted for use in other health systems
 - 17
 - 18 making this index a useful resource for researchers worldwide
 - 19
 - 20

21 Limitations

- 22
- 23 • The Rx-Risk index has been updated and mapped to ATC codes based on medicine
 - 24 availability in Australia; hence modifications may be required for use in other health
 - 25
 - 26 systems
 - 27
 - 28
 - 29
 - 30 • This study was limited to patients over 65 years of age so Rx-Risk category weights
 - 31
 - 32 derived in this study may not be applicable to younger populations.
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60

Introduction

The prevalence of multimorbidity in the population is increasing [1, 2] and patients with multiple conditions are at greater risk of adverse outcomes [3]. In observational studies, in which the aim is to determine the association between medicine use and adverse events, adjustment for multimorbidity is required to avoid biased results. Reliable methods for identifying and controlling for multiple comorbidities are required in order to make valid comparisons between treatments. The Rx-Risk is a measure for determining an individual's current comorbidities based on their prescription medicine dispensing [4, 5]. It was initially developed for predicting costs of health care [6] and was subsequently adapted to predict mortality in outpatient populations [7, 8]. Rx-Risk has been found to be a better predictor of one- and three-year mortality (one-year mortality: weighted Rx-Risk c-statistic=0.728, 95% CI=0.723-0.733, three-year mortality: 0.731, 95%CI=0.728-0.734) compared to simple prescription counts in the same time periods (one-year mortality: 0.715, 95%CI=0.710-0.720, three-year mortality: 0.718, 95%CI=0.715- 0.721) [9].

The first pharmacy based measure of comorbidity, developed in 1992, was The Chronic Disease Score (CDS) [4], consisting of 17 comorbidity categories. The CDS was subsequently updated and renamed in 2003 as the Rx-Risk-V index, consisting of 45 categories of comorbidity [10]. The Rx-Risk-V index was then adapted to only include comorbidities for which a medicine could be prescribed and therefore could be applied to prescription claims data resulting in an index based on 42 categories of comorbidity [11]. Due to continual advances in pharmaceutical disease management and as new medicines are used to treat particular diseases, e.g. treatment for hepatitis B and C, the Rx-Risk requires periodical updating and re-validation. Additionally, the original published weights for the RxRisk score

1
2
3 were calculated by predicting cost of treatment rather than risk of death which is a more clinically
4 relevant outcome [6]. A list of Rx-Risk comorbidities and their corresponding medicines
5 mapped to a standardised international coding system has not been published previously
6 and would facilitate use of the index across health systems. Other comorbidity scores such
7 as the Elixhauser and Charlson Index [12, 13] require diagnostic information in their
8 construction. The advantage of the RxRisk is that it requires prescription data only and
9 provides researchers with the ability to measure comorbidity even in a predominately
10 outpatient setting.
11
12
13
14
15
16
17
18
19
20
21
22

23 The aim of this study was to facilitate the use of the RxRisk in practice by providing a list of
24 the individual RxRisk categories mapped, using clinical expertise, to the World Health
25 Organisation's Anatomical Therapeutic Chemical (ATC) classification system [14] and to
26 determine the validity of the Rx-Risk index, in predicting one-year mortality in an outpatient
27 population.
28
29
30
31
32
33
34
35
36

37 **Method**

41 **Rx-Risk index mapping**

42 The Rx-Risk index consists of 46 comorbidity categories. For each Rx-Risk category,
43 medicines indicative of that condition were mapped (see Table 1). This mapping was
44 performed at the ATC classification level and performed by consensus between two
45 pharmacists. If an individual had ≥ 1 dispensing for a medicine in a given category then they
46 were considered to have been treated (using medicines) for that comorbidity. Medications
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in both the DVA and PBS datasets are coded using the World Health Organisation
4 anatomical therapeutic chemical (ATC) classification system [14] and PBS item codes [15].
5
6
7
8

9 10 **Data sources**

11
12 The primary data source was the Australian Government Department of Veterans' Affairs
13 (DVA's) administrative claims database. This database contains details of all prescription
14 medicines, medical and allied health services, and hospitalisations subsidised by DVA. The
15
16 current treatment population consists of 223,181 members of the Australian veteran
17 community, which includes veterans, war widows and widowers. The median age of the
18
19 DVA treatment population is 75 years and 62% are men. DVA also maintains a client file
20 containing gender, date of birth and date of death information.
21
22
23
24
25
26
27

28 External validation of the Rx-Risk index was conducted using the Pharmaceutical Benefits
29 Scheme (PBS) 10% sample of the Australian population. This dataset contains information
30 on the dispensing of prescription medicines, and includes basic demographic information
31 regarding gender, year of birth and year of death. It is maintained by the Australian
32
33 Government Department of Human Services. The current treatment population consists of
34
35 1,346,340 members of the Australian community. The median age of the PBS treatment
36
37 population is 43 years and 48% are men.
38
39
40
41
42
43

44 **Patient and Public Involvement**

45
46 Patients and public were not involved in this research. .
47
48
49
50

51 **Study population**

52
53 The DVA study population included individuals with at least one health care encounter in
54
55 the six month period from 1 July 2013 to 31 December 2013. A health care encounter
56
57
58
59

1
2
3 included any of the following: a medication dispensing, a doctor's visit, or hospitalisation.
4
5 Analysis was restricted to veterans who were DVA Gold Card holders prior to 1 July 2013
6
7 (ensuring they were eligible for all DVA subsidised services, thus the data set captured all
8
9 their health claims), and were between the ages of 65 and 100 years at 1 January 2015
10
11 (N=135,406). Inclusion criteria for the PBS cohort were people with a health care encounter
12
13 (defined as at least one medicine dispensing) in the six month period from 1 July 2013 to 31
14
15 December 2013, who were aged between 65 and 100 years at 1 January 2015 (N=303,135).
16
17 The primary outcome for this study was death recorded in 2015, hence patients were only
18
19 included if they were alive as at 1 January 2015. Rx-Risk scores were calculated separately in
20
21 each dataset using prescription claims for supplied medicines over a one-year baseline
22
23 period between 1 January 2014 and 31 December 2014.
24
25
26
27

28 **Calculating Rx-Risk scores and prescription counts**

29
30 The full Rx-Risk index has 46 comorbidity categories; however, tuberculosis, and hepatitis B
31
32 and C were removed from the Rx-Risk index for this study as the number of individuals with
33
34 these conditions in the DVA cohort was less than 10 so weights could not be generated. This
35
36 resulted in 43 categories in the validation study. The following forms of the Rx-Risk score
37
38 were generated. The unweighted Rx-Risk score was calculated as the count of the number
39
40 of different comorbidity categories for which an individual was treated with a possible score
41
42 ranging from 0 to 43. The weighted Rx-Risk score was calculated by adding the 43 indicator
43
44 variables to a logistic regression model with mortality as the outcome including age and
45
46 gender as covariates. From this model each comorbidity category was assigned a weight
47
48 according to the statistical significance and magnitude of the odds ratio generated from the
49
50 logistic regression model (Table 2)[7]. The weighted Rx-Risk score for an individual was then
51
52 the sum of the weighted indicator variables. As an example, the unweighted RxRisk score for a
53
54
55
56
57
58
59
60

1
2
3 patient who has two comorbidities 'Pain' and 'Renal disease' is 2, while their weighted Rx Score is 9
4
5 that is the sum of the weight for 'Pain' (3) and 'Renal Disease' (6).
6

7 *[Insert Table 2 here]*
8
9

10
11 Three crude prescription counts were also calculated: (i) total number of prescriptions
12 dispensed in the baseline period (1 January 2014 – 31 December 2014), (ii) total number of
13 unique medicines dispensed in the baseline period based on ATC codes, and (iii) total
14 number of unique medicines dispensed during the baseline period based on PBS item
15 codes[15]. The distinction between ATC and PBS codes was made because different
16 strengths or formulations of the same medicine have the same ATC code but different PBS
17 codes; e.g. if a patient is dispensed two different strengths of the same medicine, this will be
18 counted once in the total number of ATC medicines dispensed but twice in the total number
19 of PBS medicines dispensed.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **Statistical analysis**

35
36 Primary analysis was performed in the DVA database. A baseline logistic regression model
37 was calculated for mortality using age and gender as predictors. The comorbidity scores,
38 individual comorbidities, and crude prescription counts were added to the baseline model
39 separately. Age, comorbidity scores and crude prescription measures were included in the
40 models as continuous variables assuming linear associations. Models using the individual
41 comorbidities were developed with an indicator variable included for the presence (1) or
42 absence (0) of each individual RxRisk category. The overall goodness-of-fit of each model
43 was compared to the baseline model using the Akaike Information criterion (AIC)[16]. The
44 model with the lowest AIC value is considered the best fit. The difference between the AIC
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 values of two models must be greater than 10 for one model to be considered superior to
4
5 the other. Model discrimination was compared based on the c-statistic and the relative
6
7 Integrated Discrimination Improvement (IDI) [17]. The value of the c-statistic can range
8
9 from 0 to 1, with 1 indicating perfect prediction and 0.5 indicating chance predictions. A c-
10
11 statistic between 0.8–0.9 is generally considered as excellent, and between 0.7–0.8
12
13 acceptable[18]. Using 1000 bootstrap samples 95% confidence intervals were calculated for
14
15 the c-statistics[9].
16
17
18
19
20
21

22 **Internal validation of weighted scores**

23
24 We used 10-fold cross-validation to internally validate the binary logistic regression model
25
26 used to calculate the Rx-Risk category weights. This subsets the DVA cohort, using random
27
28 sampling without replacement, into 10 equal folds. Each fold is a 10% subset of the DVA
29
30 cohort. The training set consisted of 9 folds and was used to calculate Rx-Risk category
31
32 weights. The calculated weights were then applied to the testing set (i.e. fold left out of
33
34 training set). A binary logistic regression model of one- year mortality including age, gender
35
36 and weighted Rx-Risk was built separately for the training set and testing set and the c-
37
38 statistics recorded. This process was repeated ten times until each fold was used as the
39
40 testing set once. This resulted in 20 c-statistics being calculated, 10 each on the training and
41
42 testing set. The average c-statistic was recorded for each set.
43
44
45
46
47
48

49 **Sensitivity analyses**

50
51 Two sensitivity analyses were carried out. In the first sensitivity analysis we used the lower
52
53 confidence limit of the odds ratio to determine the Rx-Risk category weights rather than the
54
55 estimated odds ratio itself. We did this as some comorbidities are uncommon in this
56
57
58
59

1
2
3 population resulting in large confidence intervals. In the second sensitivity analysis we
4
5 calculated the Rx-Risk category weights (based on the odds ratio) generated from 5000
6
7 bootstrap samples. For each Rx-Risk category the weight was calculated as the median of
8
9 the 5000 weights for that category generated in each bootstrap sample. We did this
10
11 sensitivity analysis to test the stability of the weights.
12
13
14

15 16 **External Validation**

17
18 To determine the external validity of the weights, the calculated Rx-Risk category weights
19
20 derived from the DVA dataset were applied to the PBS cohort. The Akaike information
21
22 criterion model fit and c-statistics were calculated to determine the validity of the model.
23
24
25

26 27 **Results**

28
29 Table 1 presents the ATC mapped Rx-Risk categories, derived empirical weights, and
30
31 number of treated individuals in the DVA populations. The most frequent comorbidities
32
33 identified by the Rx-Risk index in the DVA cohort were hypertension (53%), gastro-
34
35 oesophageal reflux disease (GORD) (51%), hyperlipidaemia (50%), and conditions treated
36
37 with antiplatelets (39%). In the DVA cohort of 135,406 people, with a mean age of 83 years
38
39 (standard deviation (SD) 9.5) and 47% were men. The median unweighted Rx-Risk score was
40
41 5 (interquartile range (IQR) 3-7) and the median weighted Rx-Risk score was 3 (0-6).
42
43
44
45

46
47
48 The baseline model, comprising only age and gender, predicted one-year mortality
49
50 moderately well in the DVA cohort (c-statistic=0.738, 95% Confidence Interval (CI) 0.734-
51
52 0.742). The addition of Rx-Risk to the model increased the performance of the model:
53
54 unweighted Rx-Risk c-statistic=0.751, (95% CI 0.747-0.754), IDI=14.0%, p-value<.0001;
55
56
57
58

1
2
3 weighted Rx-Risk c-statistic=0.786, (95% CI=0.782-0.789), IDI=65.6%, p-value<.0001; 43
4
5 individual comorbidities c-statistic=0.791, (95% CI=0.788-0.795), IDI=73.9%, p-value<.0001.
6
7 The model including the 43 comorbidity indicator variables had the lowest AIC (75692),
8
9 highest c-statistic (0.791), and the highest discrimination improvement (73.9%). The models
10
11 including the weighted Rx-Risk score or 43 comorbidity measures were better predictors of
12
13 one-year mortality than any of the crude prescription measures (Table 3). Results of the
14
15 internal 10-fold cross validation were consistent with the main analysis with an average c-
16
17 statistic of 0.785 achieved over the 10 testing datasets compared to a c-statistic of 0.786 in
18
19 the primary analysis.
20
21
22

23 *[Insert Table 3 here]*
24
25
26
27

28 In the sensitivity analysis using the lower 95% confidence interval limit in the weighting
29
30 algorithm we found a very similar performance with a c-statistic of 0.787 compared to the
31
32 weighting algorithm using the estimated odds ratio (c-statistic 0.786). In the second
33
34 sensitivity analysis in which the weights were calculated from 5000 bootstrap samples we
35
36 found a similar c-statistic (0.786) compared to the primary analysis.
37
38
39
40
41

42 The PBS cohort consisted of 303,135 people, with an mean age of 75 years (standard
43
44 deviation (SD) 7.4) and 45% were men. Similar to the DVA cohort, the most frequent
45
46 comorbidities identified by the Rx-Risk index in the PBS cohort were hypertension (54%),
47
48 hyperlipidaemia (52%) and gastro-oesophageal reflux disease (GORD) (41%). When the DVA
49
50 derived Rx-risk category weights were applied to the PBS population we found a c-statistic
51
52 of 0.833 (Table 3) showing good external validity.
53
54
55
56
57
58
59
60

Discussion

This paper presents the Rx-Risk index with each comorbidity category mapped to medicines at the ATC classification level using clinical expertise. The mapped index provides a resource for researchers working with health claims data utilising ATC codes or that have mappings to the ATC codes to calculate comorbidity, based on prescription medicine dispensing's in an outpatient population. We have shown that the updated Rx-Risk was highly predictive of one-year mortality in both the populations examined and is a valid measure of comorbidity in an outpatient population and is therefore likely to be useful in a range of observational data settings.

All forms of Rx-Risk predicted mortality better than just age and sex alone. The best results for predicting one-year mortality were achieved when modelling Rx-Risk as individual comorbidities or as a weighted score. The unweighted Rx-Risk score had similar performance to simple prescription medicine counts. Internal and external validation showed that the weighted index was predictive of one-year mortality within the veteran population and show good external validity when applied to a general population setting. These results suggest that the weighted RxRisk score is likely to be generalizable to other populations. Making the ATC map available to researchers will facilitate the use of the Rx-Risk in place of comorbidity estimated simply by prescription counts.

The Rx-Risk index has been updated accounting for the introduction of new medicines to the market, making this index a useful resource for researchers. The updated Rx-Risk has 46 comorbidities, however 3 (tuberculosis, and hepatitis B and C) were removed in the analysis stage as there were insufficient cases in the DVA cohort. A younger or larger sample may have allowed these comorbidities to be assessed. For consistency, these comorbidities were

1
2
3 also excluded from the analysis in the PBS cohort despite there being few but sufficient
4
5 cases. The Rx-Risk index has been updated and mapped to ATC codes based on medicine
6
7 availability in Australia; hence modifications may be required for use in other health
8
9 systems.

10
11
12 The health care encounter inclusion criteria were not the same for both cohorts. The DVA
13
14 cohort included people with a hospitalisation or GP visit, while the PBS cohort was limited to
15
16 those with a prescription dispensing only. However, the difference across populations is
17
18 small, as 96.7% of the DVA cohort had a medication dispensed in the six month selection
19
20 period.
21
22

23
24 Comorbidity scores are often used in observational studies to reduce the potential for
25
26 confounding. The advantage of these summary scores is that they simplify the inclusion of
27
28 individual covariates for each comorbidity into a single summary score. This is a particular
29
30 advantage when sample sizes are small or the outcome under study is rare. Our analysis
31
32 demonstrated that the performance of the weighted RxRisk score performed as well as the
33
34 model which included each individual comorbidity category. Additionally, including all
35
36 individual comorbidities as indicator variables may not be appropriate in some studies, such
37
38 as those looking at the effect of a particular treatment on an adverse event when the
39
40 treatment itself is included in the construction of the comorbidity score. For example, when
41
42 determining whether the risk of NSAIDs is associated with gastrointestinal bleeds, it would
43
44 not be correct to adjust for inflammation/pain as an indicator as the medicines mapped to
45
46 this comorbidity include NSAIDs. In this scenario it would be advisable to remove
47
48 inflammation/pain as an indicator or use the weighted Rx-Risk score. Lastly, although the
49
50 weighted RxRisk score performed well in the PBS data set, which suggests that the weights
51
52
53
54
55
56
57
58
59
60

1
2
3 have a good external validity, the Rx-Risk category weights derived in this study may not be
4
5 applicable to all external populations. We limited our cohorts to patients over 65 years of
6
7 age so factors that are predictors of mortality in this age group may not be predictors in a
8
9 younger group.
10

11 12 **Conclusion**

13
14
15 The updated Rx-Risk comorbidity score is a valid measure of comorbidity and strongly
16
17 predicted one-year mortality in an outpatient population. The weighted Rx-Risk score was
18
19 found to be valid in an external population and may be useful in practice to adjust for
20
21 confounding in observational studies using medication claims data.
22
23
24

25 **Contributor statement:**

26 Research area and study design: NP MK ER EER Data acquisition: NP MK JB; data analysis
27
28 and interpretation: NP MK ER AKC LK; statistical analysis: NP MK; Mapping of the ATC codes
29
30 to the RxRisk categories; JB LK EER. All authors drafted, edited and approved the final
31
32 manuscript.
33

34 **Competing Interests:**

35 None declared for any author.
36

37 **Funding:**

38 This work was funded by the Australian Government Department of Veterans' Affairs (DVA)
39
40 as part of the Veterans' Medicines Advice and Therapeutics Education Services (Veterans'
41
42 MATES) program. EER is supported by NHMRC GNT 1110139. DVA reviewed this manuscript
43
44 before submission but had no role in the design or conduct of this research.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

61 **Data sharing Agreement:**

62 Data are available through the Australian Government Department of Veterans' Affairs

References

1. Caughey, G.E., et al., *Prevalence of comorbidity of chronic diseases in Australia*. BMC Public Health, 2008. **8**: p. 221.
2. Vogeli, C., et al., *Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs*. J Gen Intern Med, 2007. **22 Suppl 3**: p. 391-5.
3. Feinstein, A.R., *The Pre-Therapeutic Classification of Co-Morbidity in Chronic Disease*. J Chronic Dis, 1970. **23**(7): p. 455-68.
4. Von Korff, M., E.H. Wagner, and K. Saunders, *A chronic disease score from automated pharmacy data*. J Clin Epidemiol, 1992. **45**(2): p. 197-203.
5. Clark, D.O., et al., *A chronic disease score with empirically derived weights*. Med Care, 1995. **33**(8): p. 783-95.
6. Sales, A.E., et al., *Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population*. Med Care, 2003. **41**(6): p. 753-60.
7. Johnson, M.L., et al., *Adapting the Rx-Risk-V for mortality prediction in outpatient populations*. Med Care, 2006. **44**(8): p. 793-7.
8. Vitry, A., et al., *Validity of medication-based co-morbidity indices in the Australian elderly population*. Aust N Z J Public Health, 2009. **33**(2): p. 126-30.
9. Lu, C.Y., et al., *Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting*. J Clin Epidemiol, 2011. **64**(2): p. 223-8.
10. Sloan, K.L., et al., *Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument*. Med Care, 2003. **41**(6): p. 761-74.
11. Caughey, G.E., et al., *Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts*. Diabetes Res Clin Pract, 2010. **87**(3): p. 385-93.
12. Elixhauser, A., et al., *Comorbidity measures for use with administrative data*. Med Care, 1998. **36**(1): p. 8-27.
13. Charlson, M.E., et al., *A new method of classifying prognostic comorbidity in longitudinal studies: development and validation*. J Chronic Dis, 1987. **40**(5): p. 373-83.
14. Methodology., W.H.O.C.C.f.D.S. *International language for drug utilisation research*. [cited 2017 March 03]; Available from: www.whocc.no/.
15. Australian Government Department of Health and Ageing. *Schedule of Pharmaceutical Benefits*. 2017 [cited 2017 March 21]; Available from: <http://www.pbs.gov.au/>.
16. Bozdogan, H., *Akaike's Information Criterion and Recent Developments in Information Complexity*. J Math Psychol, 2000. **44**(1): p. 62-91.
17. Pencina, M.J., et al., *Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond*. Stat Med, 2008. **27**(2): p. 157-72; discussion 207-12.
18. Hosmer, D.W., *Applied logistic regression*. 2000, New York ; Chichester: Wiley.

Table 1: List of Rx-Risk comorbidity categories, corresponding Anatomical Therapeutic Chemical (ATC) codes, and score weightings in relation to 1-year mortality risk in DVA and PBS data.

Rx-Risk comorbidity category	ATC codes	DVA Data	
		N (%)	Weights for Rx-Risk score
Alcohol dependency	N07BB01-N07BB99	183 (0.1)	6
Allergies	R01AC01-R01AD60, R06AD02-R06AX27, R06AB04	16684 (12)	-1
Anticoagulants	B01AA03-B01AB06, B01AE07, B01AF01, B01AF02, B01AX05	24863 (18)	1
Antiplatelets	B01AC04-B01AC30	52525 (39)	2
Anxiety	N05BA01-N05BA12, N05BE01	15615 (12)	1
Arrhythmia	C01AA05, C01BA01-C01BD01, C07AA07	14992 (11)	2
Benign prostatic hyperplasia	G04CA01-G04CA99, G04CB01, G04CB02 ^a	9003 (7)	0
Bipolar disorder	N05AN01	231 (0.2)	-1
Chronic airways disease	R03AC02-R03DC03, R03DX05	33244 (25)	2
Congestive heart failure	C03DA02-C03DA99, C07AB02 - if PBS ^d item code is 8732N, 8733P, 8734Q, 8735R, C07AB07, C07AG02, C07AB12, C03DA04, (C03CA01-C03CC01 AND C09AA01-C09AX99, C09CA01-C09CX99) ^b	23975 (8)	2

1				
2				
3	Dementia	N06DA02-N06DA04, N06DX01	3868 (3)	2
4				
5				
6	Depression	N06AA01-N06AG02, N06AX03-N06AX11, N06AX13-N06AX18, N06AX21-N06AX26	43354 (32)	2
7				
8				
9				
10				
11	Diabetes	A10AA01-A10BX99	17550 (13)	2
12				
13	Epilepsy	N03AA01-N03AX99	15484 (11)	0
14				
15	Glaucoma	S01EA01-S01EB03, S01EC03-S01EX99	16262 (12)	0
16				
17				
18	Gastroesophageal reflux disease	A02BA01-A02BX05	69358 (51)	0
19				
20				
21	Gout	M04AA01-M04AC01	13723 (10)	1
22				
23	Hepatitis B	J05AF08, J05AF10, J05AF11	7 (0.01)	NA
24				
25				
26				
27	Hepatitis C	J05AB54, L03AB10, L03AB11, L03AB60, L03AB61, J05AE14, J05AE11-J05AE12, J05AX14, J05AX15, J05AX65, J05AB04	1 (0.0)	NA
28				
29				
30				
31				
32				
33				
34	Human immunodeficiency virus	J05AE01-J05AE10, J05AF12-J05AG05, J05AR01-J05AR99, J05AX07-J05AX09, J05AX12, J05AF01- J05AF07, J05AF09	42 (0.03)	0
35				
36				
37				
38				
39				
40				
41	Hyperkalaemia	V03AE01	197 (0.2)	4
42				
43	Hyperlipidaemia	A10BH03 ^e , C10AA01- C10BX09	67690 (50)	-1
44				
45				
46				
47	Hypertension	C03AA01-C03BA11, C03DB01, C03DB99, C03EA01, C09BA02- C09BA09, C09DA02- C09DA08, C02AB01- C02AC05, C02DB02- C02DB99, (C03CA01- C03CC01 OR C09CA01-C09CX99) ^c	71867 (53)	-1
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1				
2				
3				
4	Hyperthyroidism	H03BA02, H03BB01	992 (1)	2
5				
6	Hypothyroidism	H03AA01-H03AA02	13438 (10)	0
7				
8	Irritable bowel syndrome	A07EC01-A07EC04, A07EA01-A07EA02, A07EA06, L04AA33	1132 (1)	0
9				
10				
11				
12	Ischaemic heart disease: angina	C01DA02-C01DA14, C01DX16, C08EX02	16988 (13)	2
13				
14				
15	Ischaemic heart disease: hypertension	C07AA01-C07AA06, C07AA08-C07AB01, C07AB02 - if PBS ^d item code is not 8732N, 8733P, 8734Q, 8735R, C07AG01, C08CA01- C08DB01, C09DB01- C09DB04, C09DX01, C09BB02-C09BB10, C07AB03, C09DX03, C10BX03 ^f	49947 (37)	-1
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29	Incontinence	G04BD01-G04BD99	5554 (4)	0
30				
31	Inflammation/pain	M01AB01-M01AH06	23510 (17)	-1
32				
33	Liver failure	A06AD11, A07AA11	5034 (4)	3
34				
35	Malignancies	L01AA01-L01XX41	7689 (6)	2
36				
37	Malnutrition	B05BA01-B05BA10	16 (0.01)	0
38				
39	Migraine	N02CA01-N02CX01	708 (1)	-1
40				
41				
42	Osteoporosis/Page t's	M05BA01-M05BB05, M05BX03, M05BX04, G03XC01, H05AA02	21448 (16)	-1
43				
44				
45				
46	Pain	N02AA01-N02AX02, N02AX06, N02AX52, N02BE51	44035 (33)	3
47				
48				
49				
50	Pancreatic insufficiency	A09AA02	433 (0.3)	0
51				
52				
53	Parkinsons	N04AA01-N04BX02	4237 (3)	3
54				
55	Psoriasis	D05AA01-D05AA99,	1224 (1)	0
56				
57				
58				
59				
60				

		D05BB01 D05BB02, D05AX02, D05AC01- D05AC51, D05AX52		
	Psychotic illness	N05AA01-N05AB02, N05AB06-N05AL07, N05AX07-N05AX13	7714 (6)	6
	Pulmonary hypertension	C02KX01-C02KX05, PBS ^d item code 9547L, 9605M	40 (0.03)	6
	Renal disease	B03XA01-B03XA03, A11CC01-A11CC04, V03AE02, V03AE03, V03AE05	1816 (1)	6
	Smoking cessation	N07BA01-N07BA03, N06AX12	1145 (1)	6
	Steroid responsive disease	H02AB01-H02AB10	19106 (14)	2
	Transplant	L04AA06, L04AA10, L04AA18, L04AD01, L04AD02	102 (0.1)	0
	Tuberculosis	J04AC01-J04AC51, J04AM01-J04AM99	0	NA

^a Benign prostatic hyperplasia medicines are tested for gender - must be male. Females suffering from bladder obstructions can be prescribed medicines used to treat benign prostatic hyperplasia.

^b Must have at least two medicines prescribed with one of those medicines having an Anatomical Therapeutic Chemical (ATC) code from C03CA01–C03CC01 and the other having an ATC code from either C09AA01–C09AX99 or C09CA01–C09CX99

^c Can have medicine dispensed with an ATC code C03CA01–C03CC01 or C09AA01–C09AX99, but not both; as this would indicate chronic heart failure.

^d Pharmaceutical Benefits Scheme

^e Combination product for hyperlipidaemia and diabetes

^f Combination product for hyperlipidaemia and ischaemic heart disease: hypertension

Table 2: Weighting algorithm used to score the Rx-Risk index.*

Odds ratio	P-value	Weighted Rx-Risk score
Any odds ratio	>0.10	0
<1	≤0.10	-1
1.0 ≤ and <1.2	≤0.10	1
1.2 ≤ and <1.4	≤0.10	2
1.4 ≤ and <1.6	≤0.10	3
1.6 ≤ and <1.8	≤0.10	4
1.8 ≤ and <2.0	≤0.10	5
≥2.0	≤0.10	6

*Weights are based on the size of odds ratio quantifying the probability of mortality in an outpatient population within one year, given treatment for a specified comorbidity.

Table 3: Comparison of different Rx-Risk scoring and modelling methods to predict one- year mortality in the DVA population and external validation using the PBS population.

Models	DVA				PBS			
	AIC ^a	Difference in AIC ^b	C-statistic ^c (95% Confidence Interval)	Relative IDI, p-value	AIC ^a	Difference in AIC ^b	C-statistic ^c (95% Confidence Interval)	Relative IDI, p-value
Base model (BM): age and sex	80538.5	-	0.738 (0.734, 0.742)	-	79527.9	-	0.761 (0.756, 0.766)	-
Rx-Risk measures								
BM + unweighted Rx-Risk	79420.1	1118.4	0.751 (0.747, 0.754)	14.0%, <.0001	77029.9	2498.0	0.796 (0.791, 0.800)	25.5%, <.0001
BM + DVA weighted Rx-Risk	76102.4	4436.1	0.786 (0.782, 0.789)	65.6%, <.0001	73143.8	6384.1	0.833 (0.829, 0.837)	92.0%, <.0001
BM + 43 comorbidity indicators	75692.2	4846.3	0.791 (0.788, 0.795)	73.9%, <.0001	71689.1	7838.8	0.845 (0.842, 0.849)	114.8%, <.0001
Crude measures								
BM + prescription count	79105.9	1432.6	0.755 (0.751, 0.759)	18.6%, <.0001	76762.8	2765.1	0.799 (0.795, 0.804)	31.4%, <.0001
BM + unique ATC ^d medicine count	78374.5	2164.0	0.762 (0.758, 0.766)	29.4%, <.0001	75369.1	4158.8	0.814 (0.810, 0.818)	50.0%, <.0001
BM + unique PBS Item Code ^e medicine count	78210.2	2328.3	0.764 (0.760, 0.768)	32.1%, <.0001	75108.8	4419.1	0.816 (0.812, 0.820)	55.8%, <.0001

^a AIC: Akaike information criterion model. The model with the lowest AIC value is considered the best fit.

^b AIC score compared to the AIC score of the base model. A model with a lower score of 10 (or more) is considered superior.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

^c Possible range 0-1, with 1 indicating perfect prediction and 0.5 indicating chance prediction. A c-statistic between 0.8–0.9 is generally considered as excellent, and between 0.7–0.8 acceptable.

^d Anatomical Chemical Therapeutic classification system, count based on the number of unique ATC codes dispensed.

^e Pharmaceutical Benefits Scheme, count based on the number of unique PBS item codes dispensed.

For peer review only